SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions March listing by industry category 03/11

20110076230 - Novel substituted indoles: The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET)... Agent:

20110076231 - Temporary embolization using inverse thermosensitive polymers: One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter,... Agent: Pluromed, Inc.

20110076232 - Specific binding proteins and uses thereof: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident... Agent: Ludwig Institute For Cancer Research

20110076233 - Delivery system for cytotoxic drugs by bispecific antibody pretargeting: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least... Agent: Immunomedics, Inc.

20110076234 - Peptides comprising an isodgr motif: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit αvβ3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.... Agent: Fondazione Centro San Raffaele Del Monte Tabor

20110076236 - Compositions and methods of treatment using modulators of motoneuron diseases: The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); methods for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in living... Agent: Kinemed, Inc.

20110076235 - Genes, methods, and compositions related to neurogenesis and its modulation: The present disclosure provides methods for investigating neurogenesis, neural cell proliferation and differentiation. Specifically, the present disclosure relates to methods for identifying pharmaceutical agents capable of modulating neurogenesis and neural cell proliferation, methods of screening for genes that modulate neurogenesis and proliferation of neural progenitor cells, and methods of identifying... Agent:

20110076237 - Hydroxylated contrast enhancement agents: wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a... Agent: General Electric Company

20110076238 - Compounds for the treatment of proliferative processes: The invention relates to the use of anticholinergics for preparing a pharmaceutical composition for the prevention and treatment of proliferative processes.... Agent: Boehringer Ingelheim International Gmbh

20110076240 - Antifungal and anti-cariogenic cellobio-oligosaccharides produced by dextransucrase: Cellobio-oligosaccharides (CBO) produced by the dextransucrase-catalyzed transglycosylation reaction of sucrose and cellobiose were discovered to be effective as antifungal agents against dental caries and against fungi who rely on glucan as an integral part of the cell wall, e.g., A. terreus. The cellobio-oligosaccharides were found to be inhibitors of β-(1,3)-glucan... Agent:

20110076239 - Reduced-sweetener products, flavoring mixtures for said reduced-sweetener products and process for the production of products of this type: l

20110076241 - Tooth coating composition: To provide a tooth coating composition capable of maintaining dental caries preventing effects of CPP-ACP, such as recalcification effect and demineralization-inhibiting effect, for a long period of time, a tooth coating composition is made not to contain water, but to include (a) 0.5 to 20% by weight of a casein... Agent: Gc Corporation

20110076242 - Antimicrobially active composition having a content of bispyridium alkane (octenidine dihydrochloride): A description is given according to the invention of a composition on an aqueous basis which comprises a) 0.001 to 10% by weight bispyridinium alkane, b) 0.1 to 30% by weight nonionic surfactant, c) 0 to 40% by weight aromatic alcohol and d) 0.01 to 10% by weight polyol selected... Agent: Air Liquide Sante

20110076243 - Modified hydrophilic polymers containing hydrophobic groups: Disclosed are hydrophilic polymers such as polysaccharides, including hyaluronic acid of any origin, modified by reaction with epoxy-functional-silicones. Hydrophobic silicon, which contains chemically active groups covalently attach to the backbone of the hydrophilic polymer and gives these new, modified polymers the ability to dissolve hydrophobic compounds including oils, drugs, and... Agent:

20110076245 - Novel inverse latices that are free of oxyethylene derivatives, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same: Novel inverse latices comprising, as inverting agents, at least one compound of formula (I): R3—[O—CH2—CH(OH)—CH2]P—OH (I) in which R3 represents a linear or branched aliphatic radical comprising from 6 to 18 carbon atoms and p an integer greater than or equal to and less than or equal to 20; and... Agent: Societe D"exploitation De Produits Pour Les Industries Chimiques Seppic

20110076244 - Surface coatings for skin: The present invention relates to skin coating compositions and methods and, in particular, to coatings containing an active agent. In some embodiments, the coating may be applied to a skin surface and may be essentially colorless and transparent. In some aspects, the coating comprises a polymer and an active agent,... Agent: Pharmasol Corporation

20110076246 - Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use: where R1 comprises benzene, pyridine, pyridin-4-one, naphthalene, anthracene, phenanthrene or alkyl groups, R2 comprises hydrogen, alkyls, aryls, a carboxyl group, carboxylate esters, organic groups or biological groups, R3 comprises alkyls, aryls, a carboxyl group, carboxylate esters, organic groups or biological groups, X comprises hydrogen, lithium, sodium, potassium, rubidium, cesium, francium,... Agent:

20110076247 - Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy: Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues.... Agent: Dong-a Pharm, Co., Ltd.

20110076248 - Immunizing compositions comprising hiv-1 proviral constructs with an inactive p6 gag tsg101 uev binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface.: The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of... Agent: Myriad Genetics, Incorporated

20110076249 - Immunotherapy for immune suppressed patients: The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative... Agent: Irx Therapeutics, Inc.

20110076250 - Biodegradable absorbents and methods of preparation: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks,... Agent:

20110076251 - Novel therapeutic agents against hepatitis: This invention relates to the treatment of hepatitis infections or hepatitis diseases, in particular hepatitis C. The invention more particularly relates to the use of an inhibitor and/or repressor of a nucleic acid molecule, especially gene, which is related to the proliferation and/or replication of hepatitis viruses, in particular hepatitis... Agent:

20110076252 - Compound and method for treatment of gastroesophageal reflux: The invention relates to the use of a L-theanine for the treatment of gastroesophageal reflux disease (e.g., heart-burn) in a human or animal, including useful methods and compositions.... Agent:

20110076257 - Modified nucleotide sequence encoding glucagon-like peptide-1 (glp-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (glp-1), human cells comprising said construct and insulin-producing constructs, and method of use ther: An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like... Agent:

20110076255 - Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency: The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury—due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional... Agent:

20110076253 - Defined culture conditions of human embryonic stem cells: The present invention relates to compositions and methods for culturing stem cells, particularly embryonic stem cells. Specifically, the invention relates to a culture medium that supports proliferation of substantially undifferentiated stem cells, while maintaining potency of the cells. An an embodiment, the culture medium is defined and supports proliferation of... Agent:

20110076256 - Human neural stem cell and pharmaceutical composition for the treatment of central or peripheral nervous system disorders or injuries using same: The present invention relates to a human neural stern cell, and to a pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same. More particularly, the present invention relates to a human telencephalon-derived human neural stem cell effective in the treatment of nervous system... Agent: Industry-academic Cooperation Foundation, Yonsei University

20110076254 - Porous scaffolds for stem cell renewal: A method for expanding a population of stem cells using a porous scaffold, a porous scaffold populated with renewed stem cells, methods of administering stem cells using the porous scaffold and cells collected from the porous scaffold, and methods for tissue engineering and treating a condition treatable by administration of... Agent: University Of Washington

20110076258 - Methods of modulating t cell- dependent immune responses: The present invention provides methods and compositions for modulating at least one T cell-dependent immune response using an inhibitor of ATP-mediated T cell activation, such as oxidized ATP, for therapeutic and research purposes.... Agent: Converge Biotech Inc.

20110076259 - Detection of risk of pre-eclampsia: A method of detecting a risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the pregnant female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, comprises detecting the level of a VEGFxxxb in a sample from the pregnant... Agent:

20110076260 - Proteases producing an altered immunogenic response and methods of making and using the same: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention... Agent:

20110076261 - Antifungal drug delivery system: A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent having a pH−pKa value of 0.5 or more formulated into shampoos, creams, lotions, gels, sprays, foams, pads, films, patches, and solutions for treatment of skin disorders... Agent:

20110076263 - Endoglin antibodies: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain... Agent: Tracon Pharmaceuticals, Inc.

20110076262 - Humanized anti-fgf19 antagonists and methods using same: The present invention concerns antagonists of the FGF19/FGFR4 pathways, and the uses of same.... Agent:

20110076264 - Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for... Agent:

20110076265 - Monoclonal antibodies having homosubtype cross-neutralization properties against influenza a viruses subtype h1: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates... Agent:

20110076268 - Antibodies against human respiratory syncytial virus (rsv) and methods of use: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically... Agent:

20110076271 - Diagnostic methods and compositions for treatment of cancer: Disclosed herein are methods and compositions useful for the diagnosis and treatment of angiogenic disorders, including, e.g., cancer.... Agent: Genentech, Inc.

20110076273 - Highly concentrated pharmaceutical formulations: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of... Agent: Genentech, Inc.

20110076267 - Humanized antibody compositions and methods for binding lysophosphatidic acid: Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.... Agent:

20110076274 - Materials and methods relating to a g-protein coupled receptor: The present inventors demonstrate that the G-protein coupled receptor 55 (GPR55) is highly expressed in human aggressive breast cancer cells, and that the expression level may be correlated with the invasiveness and metastatic potential of these cells (for example metastasis to bone). In various aspects of the invention there are... Agent:

20110076269 - Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid: Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and/or... Agent:

20110076266 - Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and... Agent:

20110076270 - Therapeutic binding molecules: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising... Agent: Novartis Ag

20110076272 - Therapeutic methods and compositions: Disclosed herein are methods for modulating the environment of a tumor, by inhibiting the activity of the extracellular enzyme lysyl oxidase-like 2 (LOXL2). The methods disclosed herein are effective in reducing tumor growth, reducing recruitment of cells to the tumor, reducing fibroblast activation, reducing desmoplasia, reducing vasculogenesis, reducing the number... Agent:

20110076275 - Method of modifying isoelectric point of antibody via amino acid substitution in cdr: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising... Agent: Chugai Seiyaku Kabushiki Kaisha

20110076276 - Novel hiv reverse transcriptase inhibitors: e

20110076277 - Methods of identifying anti-inflammatory compounds: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune... Agent: The Rockefeller University

20110076281 - Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.... Agent: Genera Istrazivanja D.o.o

20110076280 - Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker: Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in... Agent: Oncotherapy Science, Inc.

20110076279 - Fully human anti-vegf antibodies and methods of using: Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies... Agent: Xoma Technology Ltd.

20110076282 - Methods of killing cells and use of same in prevention and treatment of cancer: A method of killing a cell having a mutation in an Adenomatous polyposis coli (APC) gene is disclosed. The method comprises contacting the cell with an inhibitor of Casein kinase I (CKI), the CKI being selected from the group consisting of CKI-alpha and CKI-delta and CKI-epsilon, thereby killing the cell.... Agent: Yissum Research Development Company Of The Hebrew Univeristy Of Jerusalem Ltd

20110076278 - Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders: Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor-1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized... Agent:

20110076283 - Method for predicting and diagnosing brain tumor: The present invention relates to a method for predicting or diagnosing outcome of concomitant chemo-radiotherapy of a subject suffering from brain tumor. The present invention further relates to compositions and methods for treatment or prevention of tumor resistance in a subject suffering from a brain tumor and to a kit... Agent: Universite De Lausanne

20110076285 - Methods and compositions for treatment of ocular fibrosis: Disclosed herein are methods and compositions for treatment of ocular fibrosis, as occurs, for example, during the treatment of glaucoma by trabeculectomy. Compositions comprise modulators of the activity of one or more lysyl oxidase-type enzymes (e.g., LOX, LOXL2), and the methods include methods for making the modulators and methods for... Agent:

20110076284 - Novel modulators: Antibodies that modulate insulin receptor signaling are provided.... Agent: Xoma Technology Ltd.

20110076286 - Methods of inhibiting unwanted cell proliferation using hedgehog antagonists: The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.... Agent: Curis, Inc.

20110076287 - Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods: where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and... Agent:

20110076292 - Benzoxazepin pi3k inhibitor compounds and methods of use: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the... Agent:

20110076291 - Benzoxepin pi3k inhibitor compounds and methods of use: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii)... Agent:

20110076288 - Compositions for and methods of identifying antigens: Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.... Agent: President And Fellows Of Harvard College

20110076290 - Dendritic cell vaccines for asparaginyl-beta-hydroxylase expressing tumors: A vaccine containing AAH-loaded mature dendritic cells for treatment of AAH-expressing tumors in mammalian subjects. A method of producing primed dendritic cells is carried out by contacting isolated dendritic cells with an antigen such as AAH. Following the antigen-contacting step, the dendritic cells are contacted with a combination of cytokines... Agent:

20110076295 - Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.... Agent:

20110076294 - Mixed cell populations for tissue repair and separation technique for cell processing: The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for... Agent: Aastrom Biosciences, Inc.

20110076296 - Tlr3 agonist compositions: The present invention relates generally to the fields of medicine. More specifically, the present invention relates to improved TLR3 agonists. The present invention provides novel dsRNA such as polyAU composition useful in the treatment of TLR3 related diseases, uses and preparations thereof.... Agent: Innate Pharma S.a.

20110076289 - Transgenic animal model of neurodegenerative disorders: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.... Agent: Governing Council Of The University Of Toronto

20110076293 - Triptolide derivatives for modulation of apoptosis and immunosuppression: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.... Agent:

20110076297 - Peptides for inducing heterosubtypic influenza t cell responses: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules.... Agent: Saint Louis University

20110076298 - Soluble stabilized trimeric hiv env proteins and uses thereof: This invention provides a protein comprising (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp120 envelope polypeptide portion of a gp140 envelope of (i) an HIV-I KNH1144 isolate, or a quasi-species thereof, or (ii) an HIV-I 5768.4 isolate,... Agent:

20110076301 - Antigenic protein fragments of streptococcus pneumoniae: Antigenic protein fragments of Streptococcus pneumoniae to be used for the preparation of a medicament for the prevention and the treatment of bacterial infections and a method for the detection thereof, and related compositions using said epitopes, are disclosed.... Agent:

20110076300 - Hybrid polypeptides including meningococcal fhbp sequences: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a... Agent:

20110076299 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of... Agent: Wyeth Holdings Corporation

20110076302 - Plant-derived vaccines against respiratory syncytial virus: A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV. Also disclosed are... Agent:

20110076303 - Methods for screening for anti-graying agents on the basis of aff-4: An objective of the present invention is to provide an anti-graying agent. The present invention provides a method for screening an anti-graying agent whereby a substance that increases expression of AFF-4 in cells is selected by applying a candidate substance to cells in vitro; and, an anti-graying agent containing at... Agent:

20110076304 - Adapter molecule for the delivery of adenovirus vectors: The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising... Agent: The Uab Research Foundation

20110076305 - Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for... Agent: Cook Biotech, Inc.

20110076306 - Arabinogalactan for enhancing the adaptive immune response: The present invention discloses a composition containing Arabinogalactan for enhancing the adaptive immune response in subjects to foreign antigen(s) by administering said composition prior, during and after the phase of exposure to said foreign antigen(s). Furthermore, the present invention relates to a vaccination kit comprising a composition comprising Arabinogalactan and... Agent:

20110076308 - Micelle encapsulation of therapeutic agents: The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it... Agent:

20110076307 - Polycationic gene carriers formed of endogenous amino group-bearing monomers: The present invention is directed to a design of and a method to synthesize polycations for gene (DNA and RNA) delivery. According to this design, the polycations (also said cationic polymers) are formed by polymerization of endogenous monomers bearing sufficient amino groups through degradable bonds with linker molecules or with... Agent:

20110076309 - Antiperspirant/deodorant composition: A composition in which the volatile silicone is partially or fully replaced by a plant oil. The plant oil containing composition is parity or better than the volatile silicone containing material but at lower cost. One example comprises a mixing product of at least one material chosen from antiperspirant actives... Agent:

20110076310 - Antiperspirant/deodorant composition: A composition that is gelled with a high level of fatty acid. A composition comprising at least one active chosen from an antiperspirant active and a deodorant active: a fatty acid in an amount of greater than 7 weight %; and a plant oil in an amount of at least... Agent: Colgate-palmolive Company

20110076311 - Ceramide dispersion: A ceramide dispersion, which includes at least: natural-ceramide-containing particles that are dispersed in an aqueous phase as an oil-phase component; and at least one surfactant, wherein the natural-ceramide-containing particles contain one or more natural ceramides in an amount of 50% by mass or higher with respect to the total mass... Agent: Fujifilm Corporation

20110076313 - Antimicrobial gas impregnated devices and methods: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally... Agent: Enox Biopharma, Inc.

20110076312 - Antimicrobial/antibacterial medical devices coated with traditional chinese medicines: An antimicrobial composition for coating a medical device. The antimicrobial composition includes a polymeric film forming material and an antimicrobial agent comprising a material selected from the group of extract of Houttuynia cordata, sodium houttuyfonate, sodium new houttuyfonate and mixtures thereof. A medical device having an antimicrobial composition that includes... Agent: Ethicon, Inc.

20110076314 - Hydrophobic polysaccharides with silyl ether linkages having enhanced degradation and medical articles made therefrom: Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a silyl ether chemistry that facilitates degradation of the polymer. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation... Agent:

20110076315 - Grafts and stents having inorganic bio-compatible calcium salt: The present application discusses techniques and structures that incorporate calcium salts in the luminal surface of grafts. In an embodiment, a graft, stent-graft or TIPS may incorporate bio-compatible calcium salt, which is essentially non-osteoinductive in nature, on the surfaces of the implantable device.... Agent: C.r Bard, Inc.

20110076317 - Rapid establishment and/or termination of substantial steady-state drug delivery: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of... Agent:

20110076316 - Scalable matrix for the in vivo cultivation of bone and cartilage: The present invention provides implantable receptacle devices (and methods) for use in bone and tissue regeneration which provide immediate structural stability and strength to a zone where tissue regeneration is required. By virtue of their size, shape and construction, the devices are scalable, modular, structurally stable, self-stacking in three dimensions,... Agent:

20110076318 - Retinoid-containing sustained release intraocular implants and related matters: Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is... Agent: Allergan, Inc.

20110076319 - Bioresorbable metal stent with controlled resorption: Embodiments herein relate to a special form of a bioresorbable metal stent with controlled resorption due to a wrap with a special polymer, thereby ensuring a controlled resorption of the wrapped endoprosthesis subsequent to its implantation into a blood vessel. The resorbable implant comprises a magnesium alloy provided with a... Agent:

20110076320 - Stem cell cultivation devices and methods: The present invention relates to a device and methods for culturing stem cells, and in particular, for culturing ocular stem cells and the use of stem cells cultured using the devices and methods of the invention for the treatment of diseases.... Agent:

20110076321 - Self-adhesive polymer matrix containing sea algae extract: A self-adhesive polymer matrix which comprises a polymer that forms a gel in water, water, a sea algae extract, and a monohydric or polyhydric alcohol.... Agent: Beiersdorf Ag

20110076322 - Amphoteric liposomes: A serum-stable mixture of lipids capable of encapsulating an active agent to form a liposome, said mixture comprising phosphatidylcholine and phosphatidylethanolamine in a ratio in the range of about 0.5 to about 8. The mixture may also include pH sensitive anionic and cationic amphiphiles, such that the mixture is amphoteric,... Agent:

20110076324 - Use of histamine h4 antagonist for the treatment of post-operative adhesions: The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering a histamine H4 receptor antagonist, systemically, directly to tissue surfaces in the body cavity, or both, and to delivery vehicles... Agent: Janssen Pharmaceutica Nv

20110076323 - Vaccine for alzheimer's disease: Compositions and methods for prevention and treatment of Alzheimer's disease utilize a combination of amyloid-beta protein or a fragment thereof and a heat shock protein or a fragment thereof.... Agent:

20110076325 - Abuse resistant drugs, method of use and method of making: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and... Agent: Abuse Deterrent Pharmaceutical, LLC

20110076326 - Modified protein excipient for delayed-release tablet: The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby... Agent:

20110076328 - Compositions for the treatment of hair loss: A composition for the treatment or prevention of a disorder resulting in hair loss comprises a cardiac glycoside as active principal.... Agent:

20110076327 - Herbal pain killer compositions: Disclosed are natural compositions including at least five core ingredients that provide pain relief without the side effects of synthetic pain relievers. Further provided are methods of making the disclosed herbal formulations or compositions, and methods of treating mammals that include administering the herbal compositions to a mammal in need... Agent: Ultimaxx, Inc.

20110076329 - Graft prosthesis, material and methods: A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby... Agent:

20110076330 - Use of adipose tissue-derived stromal cells in spinal fusion: The present invention encompasses methods and compositions for treating a bone condition. The isolated adipose tissue-derived stromal cell of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications such as in spinal fusion procedures.... Agent: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

20110076331 - Use of deuterium oxide as an elastase inhibitor: The invention relates to the use of deuterium oxide (D2O) as an elastase inhibitor and especially as an inhibitor of the human neutrophil elastase (HNE). The invention also relates to the use of deuterium oxide for the prophylaxis and/or treatment of HNE-related diseases.... Agent:

20110076332 - Dextran-chitosan based in-situ gelling hydrogels for biomedical applications: A biodegradable hydrogel comprises a water-soluble dextran having aldehyde groups cross-linked with a water-soluble chitosan. Various chemical agents may be encapsulated in the hydrogel or bonded thereto for controlled release. The hydrogel may be applied as a coating to reduce the likelihood of bacterial attachment and biofilm growth; used in... Agent:

20110076333 - Method and compositions for selectively treating skin: This invention relates to compositions, methods and kits for selectively depositing a benefit agent on skin without depositing the benefit agent on the hair. The method relates to exposing the skin to a composition containing anionic proteins, anionic polymers, anionic dyes, anionic pigments, or mixtures thereof which have an isoelectric... Agent:

20110076334 - Methods and compositions for treatment of raynaud's phenomenon: Administration of a calcium channel blocker such as clevidipine or nicardipine in aerosol dry powder form directly to a patient's lungs for treating Raynaud's Phenomenon.... Agent:

20110076336 - Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof: A method of making a dry powder pharmaceutical composition comprising: providing inactive ingredient particles; providing a micronized active ingredient; mixing the inactive ingredient particles with surface-modified nanoparticles to provide an inactive ingredient comprised of particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and/or mixing the micronized active... Agent:

20110076335 - Novel lipid formulations for delivery of therapeutic agents to solid tumors: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or... Agent: Protiva Biotherapeutics, Inc.

20110076337 - Emulsions containing arylboronic acids and medical articles made therefrom: The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion,... Agent:

20110076338 - Composition for skin protection and methods of making same: Skin care formulations having tamanu oil in amounts providing effective rates of protection for antimicrobial and anti-aging properties, including but not limited to promoting the formation of new tissue, scar healing and skin repair, anti-inflammatory, anti-bacterial, anti-fungal, anti-oxidant, and combinations thereof.... Agent:

20110076339 - Colon cleansing method and kit: A method of colon cleansing that provides superior cleansing. In an embodiment, superior cleansing of the right colon is provided. In an embodiment, a stimulant laxative is consumed at least two days prior to the day for which maximum cleansing is desired, and an osmotic purgative is consumed one day... Agent: Kingston General Hospital

20110076340 - Cleaning compound for cleaning surfaces in a food processing environment: A cleaning compound for cleaning surfaces in a food processing environment includes at least one container, with each container including a peroxide and/or an alkaline reactant therein. The alkaline reactant is selected to raise the pH of the cleaning compound into the alkaline range when the peroxide and the alkaline... Agent: Wayne Chemical, Inc.

20110076341 - Trace elements: A trace element solution includes at least the metals: zinc, manganese, selenium, and copper, and comprises a concentration of the metal(s) of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at... Agent:

20110076342 - Cancer peptide therapeutics: Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancerous cells and also augment cytotoxic effects of chemotherapeutics.... Agent:

20110076343 - Multiple myeloma treatments: Methods for treating cancer by using compound PM00104, in particular, for treating multiple myeloma are provided.... Agent: Pharma Mar, S.a.

20110076344 - Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response: Methods of using a stabilized chlorite solution to inhibit antigen-specific immune responses are disclosed. The stabilized chlorite solution, when administered to a mammal in need thereof, can prevent the presentation of antigens by antigen presenting cells. The stabilized chlorite solution therefore is useful in treating, inter alia, auto-immune diseases, treating... Agent: Dimethaid Ag

20110076345 - Herbal formulation for the treatment of bone fractures and osseous defects: An herbal formulation including Symphytum Officinalis extract and Phytolacca Decandra extract may be combined to treat bone fractures and osseum defects. Specifically, the herbal formulation provides for the regeneration of osseum tissue for treating bone defects such as imperfect osteogenesis, pseudo-arthrosis infected or not, bone union delay of fractures, osteoporosis,... Agent:

20110076346 - Novel compositions from nigella sativa: Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w/w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful... Agent:

20110076347 - Molecules interfering with binding of calbindin to inositol monophosphatase for the treatment of mood disorders: This invention provides derivatives of dodecapeptide ISSIKEKYPSHS which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.... Agent:

20110076348 - Prophylactic and/or therapeutic agent for atopic dermatitis: To provide a prophylactic and/or therapeutic agent for atopic dermatitis with minimal concerns of adverse drug reactions and high safety, various researches were conducted. As a result, it was found that an extract extracted from a mangosteen (Garcinia mangostana L.) peel with a polar solvent prevented or healed atopic dermatitis.... Agent: Lotte Co., Ltd.

20110076349 - Composition containing hot-water extract of plant of the genus hemerocallis and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement: A composition is provided, containing an extract of a plant of the genus Hemerocallis as an active ingredient and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement. A composition is also provided, containing a hot-water extract of a plant of the genus Hemerocallis as an active ingredient and... Agent:

20110070153 - Artificial cells: The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.... Agent: Searete, LLC, A Limited Liability Corporation Of The State Of Delaware

20110070154 - Artificial cells: The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.... Agent:

20110070155 - Anti-cd74 immunoconjugates and methods: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.... Agent: Immunomedics Inc.

20110070156 - Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy: Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate... Agent: Immunomedics, Inc.

20110070157 - Radiometal-labeled amino acid analogs, imaging and therapeutic agents incorporating the same, and methods using the same: An amino acid analog is provided, in syn-stereoisomeric form, anti-stereoisomeric form, or a combination thereof. The amino acid analog includes a cyclobutane ring with at least one of an amine group and a carboxyl group attached to one carbon node of the cyclobutane ring. A chain of moieties X, Y,... Agent:

20110070159 - Compositions comprising red microalgae polysaccharides and metals: Provided is a composition which contains a red microalga polysaccharide and a heavy metal, which is used as a cosmetic, diagnostic, or pharmaceutical formulation. The pharmaceutical formulation may be employed topically or for treating nutritional and other disorders.... Agent: Ben-gurion University Of The Negev Research And Development Authority

20110070158 - Quality control module for biomarker generator system: A sample card and automated quality control module for a radiopharmaceutical synthesis system for conducting quality control tests on approximately one (1) unit dose of a radiopharmaceutical biomarker for use in positron emission tomography. The sample card and quality control module allow operators to conduct quality control tests in reduced... Agent:

20110070161 - Active enantiomer: The present invention provides a PET tracer that has improved properties for imaging the peripheral benzodiazepine receptor (PBR) as compared with known such PET tracers. The present invention also provides a precursor compound useful in the preparation of the PET tracer of the invention and methods for the preparation of... Agent: Ge Healthcare Limited

20110070160 - Dose synthesis mosule for biomaker generator system: A microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, one (1) unit dose of a radiopharmaceutical biomarker for use in positron emission tomography (PET). The radiopharmaceutical production system includes a reaction vessel that receives a radioisotope from an accelerator or other radioisotope generator.... Agent:

20110070163 - Cancer cell migration and cancer cell invasion inhibitor: Provided are an antibody which binds specifically PAR1 (protease activated receptor 1) or a fragment of the antibody which retains similar characteristics thereto; a composition containing the same for inhibiting the migration activity and invasion activity of cancer cells; and a medicinal composition for treating cancer and the like.... Agent: Tohoku University

20110070164 - Post release modification of viral envelopes: The present invention relates to enveloped virus particles providing a modified composition of their envelope, methods for exogenously modifying the envelope composition of an enveloped viral particle making use of compounds consisting of a hydrophilic target domain and a lipophilic membrane anchor domain, wherein the lipophilic membrane anchor domain becomes... Agent:

20110070162 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Max-phanck-gesellschaft Zur Foerderung Der Wissenschaften E.v.

20110070165 - Multivalent constructs for therapeutic and diagnostic applications: The invention provides compositions and methods for therapeutic and diagnostic applications.... Agent:

20110070166 - Reduced dye probes for the detection of radical oxygen species: Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π... Agent: Emory University

20110070168 - Macrocyclic peptides as inhibitors of viral replication: The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions... Agent: Achillion Pharmaceuticals, Inc.

20110070167 - Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants: ATIII is a serine proteinase inhibitor (serpin) with anti-coagulant, anti-inflammatory, anti-proliferative and anti-angiogenic properties. The invention features methods of treating a subject having lung injury due to burns and smoke inhalation by administering a synergistic combination of antithrombin III and heparin through pulmonary delivery means.... Agent:

20110070169 - Effervescent oral fentanyl dosage form and methods of administering fentanyl: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.... Agent: Cima Labs Inc.

20110070170 - Manufacture of chewing gum product with radiofrequency: The present invention features a process for making a chewing gum product including the steps of forming a powder blend containing a gum base into the desired shape of the chewing gum product and applying radiofrequency energy to the shape for a sufficient period of time to soften the gum... Agent:

20110070171 - 1-tert-butylcyclohexanecarboxamide and uses thereof as cooling compounds: wherein X, Y is independently selected from a C1-C4 straight or branched alkyl or H atom; and R1 is selected from a linear or branched alkyl, alkenyl, alkynyl, alkoxyalkyl containing from 1 to 6 carbons or group (CH2)n-Z, where n is 0 to 6 and Z is a group with... Agent:

20110070172 - Rebaudioside c and its stereoisomers as natural product sweetness enhancers: The present invention is directed to the use of rebaudioside C, or a stereoisomer thereof, for enhancing the sweet taste of carbohydrate sweeteners, such as sucrose and fructose. The present invention is also directed to consumables comprising a combination of a carbohydrate sweetener and rebaudioside C, or a stereoisomer thereof.... Agent:

20110070174 - Benzoyl peroxide and sunscreen agent combination: A topical treatment for acne vulgaris comprising benzoyl peroxide and a sunscreen base in a stable compound and methods of manufacture and use. The finished compound being in cream, lotion, gel or other topical formulations.... Agent: PrugenIPHoldings, Inc.

20110070173 - Oil-in-water type emulsion cosmetic composition: t

20110070175 - Use of organomodified siloxane block copolymers as care active ingredient for the care of human or animal body parts: The present invention relates to the use of organomodified siloxane block copolymers as care active ingredient for the care of human or animal body parts.... Agent: Evonik Goldschmidt Gmbh

20110070176 - Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.... Agent: Galderma Research & Development

20110070177 - Cosmetic packaging and application combination for shear-thinning compositions: The present invention relates to a cosmetic packaging and application combination for making up and/or caring for keratinous substances including 1) a container holding a cosmetic composition in the water-in-oil emulsion form and characterized by a certain rheological profile and 2) an applicator.... Agent: L'oreal

20110070178 - Pre-shave preparation with enhanced lubricity: A pre-shave composition to lubricate skin, comprising at least one polyfluoroalkyl dimethicone polymer, a volatile component to serve as a carrier to the polyfluoroalkyl dimethicone polymer, and a suspending agent to suspend the polyfluoroalkyl dimethicone polymer in the volatile component.... Agent:

20110070180 - Compositions for imparting superhydrophobicity: Compositions and methods are disclosed for imparting water repellency to the hair. The compositions generally comprise a first hydrophobic particulate material having a coefficient of dynamic friction of 0.5 or greater in combination with a second hydrophobic particulate material having a coefficient of dynamic friction less than 0.5.... Agent: Avon Products, Inc.

20110070179 - Cationic alcohols and uses thereof: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.... Agent: Living Proof, Inc.

20110070181 - Freshening compositions comprising malodor binding polymers and malodor counteractants: Freshening compositions comprising a malodor binding polymer, a malodor counteractant comprising at least one aliphatic aldehyde, and an aqueous carrier, wherein the composition is essentially free of any material that would soil or stain fabric; and methods thereof are provided. In some embodiments, the malodor binding polymer comprises a homopolymeric... Agent:

20110070182 - Freshening compositions comprising malodor binding polymers: Freshening compositions comprising a malodor binding polymer and an aqueous carrier, wherein the composition is essentially free of any material that would soil or stain fabric; and methods thereof are provided. In some embodiments, the malodor binding polymer comprises a homopolymeric polyethylenimine having a molecular weight of about 1,000 to... Agent:

20110070183 - Crosslinked polysiloxanes, a process for their preparation and use of the crosslinked polysiloxanes in emulsifier systems for water-in-oil emulsions: The invention relates to crosslinked organopolysiloxanes which are linked by a polyether building block via the Si atoms, to emulsifier systems which have these crosslinked organopolysiloxanes, and also to cosmetic, dermatological or pharmaceutical formulations comprising a crosslinked organopolysiloxane or an emulsifier system comprising these.... Agent: Evonik Goldschmidt Gmbh

20110070184 - Methods and compositions for treating atherosclerosis and related condidtions: Described herein are methods for treating or preventing a atherosclerosis by inhibiting the activation or binding of macrophage migration inhibitory factor to CXCR2 and CXCR4. Such inhibition is achieved by administration of either a single agent or a combination of agents. Also described herein are agents that inhibit MIF-binding or... Agent: Carolus Therpeutics, Inc.

20110070188 - Bab triblock polymers having improved release characteristics: Improved biodegradable and bioabsorbable BAB-block copolymers exhibiting reverse thermal gellation properties, and aqueous polymer compositions including the BAB-block copolymers, are provided. Methods of making the improved BAB-block copolymers and compositions including the same are also provided.... Agent: Protherics Salt Lake City, Inc.

20110070189 - Heterocyclic antiviral compounds: Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent:

20110070190 - Heterocyclic antiviral compounds: m

20110070185 - Identification of antigenic peptides from multiple myeloma cells: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure,... Agent:

20110070187 - Methods for the preparation of hcv polymerase inhibitors: The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I).... Agent: Pfizer Inc.

20110070186 - Methods of treating cancer using growth factor retargeted endopeptidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.

20110070191 - T cell receptor fusions and conjugates and methods of use there of: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and... Agent:

20110070194 - 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both... Agent: Gilead Sciences, Inc.

20110070193 - Anti-infective agents and uses thereof: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts,... Agent: Abbott Laboratories

20110070192 - Method of preparation of novel nucleoside analogs and uses: Processes for the preparation of racemic and optically active nucleoside analogs of formula (A) are described. These compounds are useful as anti-infective agents, antisense therapeutic agents and hybridization assay probes.... Agent:

20110070195 - Uses of spatial configuration to modulate protein function: This invention provides a set of methods for modulating protein spatial configuration. First, select the amino-acid codon for encoding the target protein according to host codon usage. Second, choose combinations which can modulate the spatial configuration and construct into different vectors which can transfect a series of hosts. Third, choose... Agent:

20110070196 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent:

20110070197 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent:

20110070198 - Plant-based biocidal materials and systems: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material.... Agent: Metaactiv, Inc.

20110070208 - Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof: There is provided at least one isolated cell comprising at least one HBV epitope-reactive exogenous T cell receptor and/or fragment thereof, and methods for producing them. In particular, there is provided polynucleotides, constructs and vectors encoding at least one HBV epitope-reactive exogenous T cell receptor for use in the treatment... Agent: Agency For Science, Technology And Research

20110070200 - Abrogating proinflammatory cytokine production during oncolytic reovirus therapy: Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.... Agent: Oncolytics Biotech Inc.

20110070199 - Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases: Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver ribosomal RNA molecules along with messenger RNA... Agent:

20110070204 - Medium for handling and storing biological tissues of the musculoskeletal system outside an organism: The present disclosure relates to a medium for handling, including storing, cultivating, coating, impregnating and/or preserving musculoskeletal tissues such as bone, cartilage, tendon, muscle, nerve, ligament, blood vessel, skin, fascia, bursa and joint capsule tissue or cells, wherein the medium is an aqueous solution comprising hyaluronan and a first saccharide,... Agent:

20110070203 - Mesendoderm and mesoderm cell populations: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.... Agent: Mount Sinai School Of Medicine Of New York University

20110070206 - Methods of applying physical stimuli to cells: We describe herein methods for applying physical stimuli to cells, including mesenchymal stem cells, in culture or in vivo. These methods can be applied in, and are expected to benefit subjects in, a great variety of circumstances that arise in the context of, for example, traumatic injury (including that induced... Agent: The Research Foundation Of State University Of New York

20110070201 - Mucosal or enteral administration of biologically active macromolecules: A method of systemically delivering a biologically active, recombinant biomolecule, in a biologically active form, to a subject in need thereof. , the method comprising, enterally or mucosally administering to the subject a therapeutically effective amount of plant cells expressing an exogenous biologically active recombinant biomolecule, thereby systemically delivering the... Agent: Protalix Ltd.

20110070205 - Multipotent stem cells and uses thereof: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further... Agent: The Brigham And Women's Hospital, Inc.

20110070202 - Targeted delivery to the brain of magnetically labeled stem cells: Provided herein is a method of targeting stem cells to a specific region of the central nervous system of an individual in need of such treatment, comprising the steps of administering stem cells containing a superparamagnetic nanoparticles to said individual; and applying an external source of a magnetic field to... Agent:

20110070207 - Therapeutic composition for atopic dermatitis: A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.... Agent:

20110070209 - Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs: Acute and chronic diseases of the organs are treated in patients using a rational, multi-tier approach. A patient can be pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or... Agent:

20110070210 - Systems and method for homeostatic blood states: Decades of investigations were focused on finding “gold standard” for evaluation of plasma dilution and osmolality, blood loss evaluation and prediction of bleeding or transfusion induced changes in hematocrit and hemoglobin concentration. Addressing deficiencies of existing methods, the current invention created new combined mathematical-physiological model applicable to manually operated nomograms... Agent: Meditasks, LLC

20110070214 - Bacitracin metal complexes used as bleach catalysts: Bacitracin, bacitracin derivatives and other oligopeptides, alone or in the form of oligopeptide-metal ion complexes, are shown to be useful as bleach catalysts incorporated in washing and cleaning agents for the cleaning of soiled hard surfaces and textile fabrics. These catalysts may be used in conjunction with hydrogen peroxide or... Agent: Henkel Ag & Co. Kgaa

20110070213 - Dermal compositions containing coenzyme q as the active ingredient: which comprises applying, to a patient suffering from a skin disease, the above therapeutic agent for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) in parallel with a therapeutic composition for skin diseases.... Agent: Kaneka Corporation

20110070211 - Methods of treating cancer using galanin retargeted endopepidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.

20110070212 - Methods of treating cancer using glucagon-like hormone retargeted endopeptidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.

20110070215 - Methods of treating cancer using neurotrophin retargeted endopeptidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.

20110070217 - Compositions and methods for treating hiv infection with cupredoxin and cytochrome c: The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurin, and/or Pseudomonas aeruginosa cytochrome c551 and their use in inhibiting of viral infection, and in particular infection of mammalian cells by the Human Immunodeficiency Virus (HIV). The invention also relates to variants and derivatives of cupredoxin and cytochrome c that... Agent:

20110070216 - Therapeutic combination comprising a pulmonary surfactant and antioxidant enzymes: Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress.... Agent: Chiesi Farmaceutici S.p.a.

20110070218 - Methods of treating cancer of the central nervous system: A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer... Agent:

20110070219 - High pressure protein crystallization: The present disclosure provides an effective method for the crystallization of proteins at high pressure. A preferential excluding agent, and optionally other reagents may be incorporated into the method. The method is applicable to substantially all proteins.... Agent:

20110070220 - Immunomodulating gene therapy: The present invention relates, in general, to Pompe disease and, in particular, to a methods of treating Pompe disease and to compounds/constructs suitable for use in such methods.... Agent: Duke University

20110070221 - Gnaq mutations in melanoma: The present invention provides methods of detecting mutations in a Gnaq gene in a melanocytic neoplasm for diagnostic and prognostic purposes. The invention further provides methods of treating such melanocytic neoplasm by modulating the activity of the mutated Gnaq gene.... Agent: The Regents Of The University Of California

20110070224 - Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue: A delivery device including at least one stinging capsule and methods of use are described.... Agent: Nanocyte Inc.

20110070222 - Therapeutic modulation of ocular surface lubrication: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular... Agent: Schepens Eye Research Institute

20110070223 - Uses of lp-pla2 in combination to assess coronary risk: This invention relates to a method for assessing risk of Coronary Vascular Disease (CVD). Specifically, it relates to utilizing risk assessment from both Lipoprotein Associated Phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) in combination. In addition the invention relates to a method for assessing risk of Coronary Vascular Disease (CVD)... Agent: Diadexus, Inc.

20110070225 - Beta antibody parenteral formulation: The present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation. Furthermore, corresponding uses are described.... Agent:

20110070232 - Combination therapy with an antitumor alkaloid: The present invention relates to combinations of PM00104 with other anticancer drugs, and the use of these combinations in the treatment of cancer.... Agent: Pharma Mar, S.a.

20110070228 - Method and apparatus for automated cell transfer therapy and hair transplantation: Methods and apparatuses that selectively capture therapeutic cells associated with hair growth or development and their delivery to regions of hair loss. Cell capture and delivery is accomplished in part through the use of antibodies having binding sites specific to cell surface moieties characteristic of the therapeutic cells and having... Agent: Surgimed Biosciences, Inc.

20110070230 - Method and devices for identifying and treating a subject who has developed an anti-antibody response: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the... Agent: Xbiotech, Inc.

20110070229 - Method of selecting a monoclonal antibody for administration: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the... Agent: Xbiotech, Inc.

20110070231 - Stable liquid pharmaceutical formulation of igg antibodies: This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that... Agent: Abbott Biotherapeutics Corporation

20110070227 - Treatment of autoimmune and inflammatory diseases: The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.... Agent:

20110070226 - Variable antibodies: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the... Agent:

20110070233 - Actriib antagonists and dosing and uses thereof: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.... Agent: Acceleron Pharma Inc.

20110070235 - Compositions and methods for the therapy and diagnosis of influenza: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.... Agent:

20110070237 - Methods of modulating and identifying agents that modulate intracellular calcium: Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.... Agent: Calcimedica, Inc.

20110070234 - Np1 activity regulating elements useful for the production of drugs for the treatment or prevention of human neurodegenerative diseases, resulting drugs and use thereof: The invention relates to a series of compounds useful for the production of drugs or pharmaceutical compositions for the treatment or prevention of human neurological diseases, preferably neurodegenerative diseases, which inhibit the activity of the human NP1 protein which acts as an inducer of neurodegeneration and neural apoptosis. Said compounds... Agent: Consejo Superior De Investigaciones Cientificas

20110070236 - Use of immunesuppressant receptor: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and... Agent: Ono Pharmaceutical Co., Ltd.

20110070238 - Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.... Agent: Inserm - Institut National De La Sante Et De La Recherche Medicale

20110070239 - Anti-ox40l antibodies: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.... Agent:

20110070242 - Methods for diagnosing and treating iron dysregulation: The present invention relates to methods for diagnosing and treating iron overload and iron deficiency.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20110070241 - Methods for modulating immune responses to aav gene therapy vectors: The present disclosure provides methods of inhibiting an immune response to a viral vector used in gene therapy, such as adeno-associated virus (AAV), which involves co-administration of viral vector and an interfering molecule. The interfering molecule functions by either disrupting the TLR9-MyD88-type I IFN signaling pathway and/or neutralizing Type I... Agent: Duke University

20110070240 - Methods of treating b-cell cancers: The present invention is directed to methods of causing malignant B-cells and treating malignant B-cells. These methods involve the use of an inhibitor of PKK activity, whether active directly against PKK or effective to knockdown PKK expression, which when introduced into a malignant B cell (or administered to a patient)... Agent: University Of Rochester

20110070243 - Compositions and methods for the treatment of tumor of hematopoietic: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent:

20110070244 - Methods for the treatment of multiple myeloma: Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease.... Agent: The Cbr Institute For Biomedical Research, Inc.

20110070246 - Antibodies against cdcp1 for the treatment of cancer: The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.... Agent: F. Hoffmann-laroche Ag

20110070245 - Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer: IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P<0.0001), low-histological grade (P=0.0001), and poor prognosis (P=0.0053). Suppression of IMP-1 expression with siRNA effectively suppressed growth of NSCLC cells. IMP-1 was able to bind to mRNAs... Agent: Oncotherapy Science Inc.

20110070247 - Protein modulators: The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment... Agent: Novartis Ag

20110070248 - Dr5 ligand drug conjugates: Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers.... Agent: Daiichi Sankyo Co., Ltd.

20110070249 - Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of... Agent: Ramot At Tel-aviv University Ltd.

20110070250 - Therapeutical composition containing dentritic cells and use thereof: The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist... Agent:

20110070251 - Cancer vaccine composition: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.... Agent: International Institute Of Cancer Immunology, Inc.

20110070252 - Mage-a3/hpv 16 peptide vaccines for head and neck cancer: The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the... Agent: University Of Maryland, Baltimore

20110070253 - Tumour-associated peptides binding to mhc molecules: The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC)... Agent: Immatics Biotechnologies Gmbh

20110070254 - Mutations in the influenza a virus ns1 gene and use thereof: NS1 variant polypeptides, proteins or functional fragments thereof are described which have useful properties for increasing viral protein synthesis, IFN induction, and IFN resistance. The NS1 variant polypeptides, proteins or functional fragments comprise a substitution in the amino acid sequence of the wild type NS1 protein at a position corresponding... Agent: University Of Ottawa

20110070255 - Immunogenic peptide composition for the prevention and treatment of alzheimer's disease: The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II... Agent: United Biomedical, Inc.

20110070256 - Vaccine antigens from piscirickettsia salmonis: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses... Agent: Intervet International B.v.

20110070257 - Polyvalent chimeric ospc vaccinogen and diagnostic antigen: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.... Agent:

20110070258 - Method of slowing the aging process by activating sirtuin enzymes: The fucoxanthin/pomegranate seed oil composition describes a method of slowing the aging process in a mammalian subject by activating at least one member of the sirtuin family of proteins, wherein the activating step includes administering to the subject a synergistic combination of fucoxanthin and punicic acid. Sirtuin enzymes exert their... Agent: Polifenoles Naturales, S.l.

20110070259 - Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached... Agent:

20110070260 - Multivalent immunogenic compositions against noroviruses and methods of use: The invention provides immunogenic formulations comprising virus-like particles (VLPs) from two or more genoclusters and/or strains of norovirus in a pharmaceutically acceptable carrier. In representative embodiments, the formulation also comprises an adjuvant, for example, a viral adjuvant or CpG. The invention also provides methods of inducing an immune response to... Agent:

20110070261 - Combination vaccines against mycobacterium sp. and methods of using the same: The invention relates to a combination vaccine against Mycobacterium avium subspecies paratuberculosis (MAP) and M. tuberculosis and/or M. bovis for use in methods of immunizing a subject against mycobacterial infection, preventing or treating mycobacterial infection, and preventing a disease associated with mycobacterial infection.... Agent:

20110070262 - Viral vectors and their use in therapeutic methods: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.... Agent:

20110070263 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC

20110070264 - Rabies virus vector systems and compositions and methods thereof: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the... Agent: Of Health And Human Services, Centers For Disease Control And Prevention

20110070265 - Engineered pertactin variants for vaccine use: The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B.... Agent:

20110070266 - Immunogenic compositions for chlamydia trachomatis: The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for... Agent:

20110070267 - Packaged virus-like particles for use as adjuvants: method of preparation and use: The invention relates to the finding that virus like particles (VLPs) can be loaded and packaged, respectively, with DNA oligonucleotides rich in non-methylated C and G (CpGs). If such CpG-VLPs are mixed with antigens, the immunogenicity of these antigens are dramatically enhanced. In addition, the T cell responses against the... Agent:

20110070269 - Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof: This disclosure provides, in certain embodiments, methods for generating and using extracts of Pyrularia (e.g., Pyrularia pubera) and/or epiphytic/endophytic bacteria associated therewith, either alone or in combination with conventional immunostimulant(s) or anti-inflammatory agents, for modulation of the immune system of a subject. Also provided are compositions that include specific Pyrularia... Agent: Therapro Technologies, Inc.

20110070268 - Method: Methods for characterisation of patients as responders or non-responders to therapy based on differential expression of one or more genes are provided. Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods of treatment are also provided. The kits and methods relate... Agent: Glaxosmithkline Biologicals Sa

20110070270 - Immunostimulating agent: An immunostimulating agent, which can stimulate immunity effectively, is described. The immunostimulating agent contains an active ingredient including a calcium receptor activator such as γ-Glu-X-Gly [wherein X represents an amino acid or a derivative thereof other than Cys], γ-Glu-Val-Y [wherein Y represents an amino acid or a derivative thereof], γ-Glu-Ala,... Agent:

20110070271 - Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles: Constructs that are at least partially constructed of allograft cancellous bone are disclosed, along with cartilage particles that may be used with the constructs for repairing articular cartilage defects. A multi-piece construct includes a base member, a cap member and at least one pin that secures the cap member to... Agent:

20110070272 - Materials and methods for modulating metabolism: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound... Agent:

20110070275 - Crystalline pyrithione/zinc oxide composite and physiologic/antibiotic composition containing the same: It has been elucidated that a new composite of the present invention obtained by treating an aqueous suspension or an aqueous paste containing zinc pyrithione or a zinc pyrithione/zinc oxide complex compound and ultrafine zinc oxide having an average particle diameter of 0.01 to 0.15 μM at pH 8 to... Agent:

20110070274 - Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide: Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.... Agent: Galderma Research & Development

20110070273 - High-coverage and natural-looking cosmetic compositions and uses thereof: Topical compositions comprising at least one matte-finished interference pigment combined with one or more microsphere(s) and elastomer(s) are provided, as well as methods for using such compositions in cosmetics and dermatological products that afford high coverage of flaws or imperfections, while maintaining a natural-looking appearance. These cosmetics and dermatological products... Agent: Avon Products, Inc.

20110070276 - Bioactive keratin peptides: Compositions containing biologically active peptides are disclosed. Active peptides are isolated fragments derived from human hair or sheep wool keratin proteins. Compositions may be prepared for pharmaceutical or topical administration or for use in cosmetic preparations.... Agent: Keraplast Technologies, Ltd.

20110070277 - Substrate comprising a lotion composition limiting the adherence of feces or menses to the skin: A lotion composition applied on the body facing surface of an absorbent article such as a diaper, training pant, adult incontinence product, feminine hygiene product, improves the ease of removal of feces or menses after an absorbent article comprising the lotion composition has been used and removed from the wearer.... Agent:

20110070278 - Metconazole compositions and methods of use: The invention generally relates to fungicidal non-aqueous, dispersible concentrate (DC) compositions comprising metconazole, non-ionic surfactants, and solvents. Methods of use and ready-to-use products are also provided.... Agent:

20110070279 - Anti-bug fabric: An anti-bug fabric is a flat piece of fabric and composed of multiple longitudinal strings and multiple altitude strings which are weaved to the longitudinal strings. Each of the longitudinal strings and altitude strings includes an inner portion and an outer portion which wraps to the inner portion, wherein the... Agent: Jone-shou Industrial Co., Ltd

20110070280 - Method for differentiating embryonic stem cells into cells expressing aqp-1: The present invention relates to methods of differentiating a human embryonic stem (ES) cell into a cell, specifically a renal epithelial cell, expressing AQP-I. The methods disclosed comprise culturing human ES cells in a renal specific medium in the presence of an extracellular matrix molecule. The cells produced according to... Agent:

20110070281 - Reparative cell delivery via hyaluronic acid vehicles: Methods are described for generating autologous tissue grafts, including generating grafts at the point of case, which include isolated cell populations that are enriched with stem cells and are mixed with hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen... Agent:

20110070283 - Coating for implantable devices and a method of forming the same: Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.... Agent: Advanced Cardiovascular Systems, Inc.

20110070282 - Materials and methods for treating skeletal system damage and promoting skeletal system repair and regeneration: Disclosed herein are materials and methods suitable for treating injured, damaged or diseased mineralized and non-mineralized skeletal tissues, including bones, joints, tendons, ligaments, cartilage and/or other non-mineralized skeletal tissues. The affected structure can be treated by contacting a surface of the skeletal element at or adjacent to or in the... Agent: Pervasis Therapeutics, Inc.

20110070284 - Biologic matrices comprising anti-infective methods and compositions related thereto: Described herein are methods and compositions related to biologic matrices comprising at least one anti-infective. In certain embodiments, the invention relates to a biologic matrix comprising a slowed release anti-infective agent. In a particular embodiment, the invention relates to an acellular dermal matrix comprising a slowed release antiinfective agent, wherein... Agent: Musculoskeletal Transplant Foundation

20110070285 - Method of making flexible bioresorbable hemostatic packing and stent having a preselectable in-vivo residence time: The invention provides a method of making flexible bioresorbable foam having hemostatic properties and a preselectable in-vivo residence time. A blend of crosslinked collagen blended and a hyaluronic acid component is prepared. The blend is mixed with water to form a suspension. The blend is freezed and lyophilized at less... Agent: Medtronic Xomed, Inc.

20110070287 - Film-coated compressed chewing gum: A compressed chewing gum tablet includes at least one compressed chewing gum module, the at least one compressed chewing gum module including a compressed particulate chewing gum composition, which compressed particulate chewing gum composition includes compressed chewing gum particles containing gum base. The content of gum base is at least... Agent:

20110070286 - Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process: A process for making a nicotine-comprising chewing gum by (i) dispensing a powder portion from a gum-base-comprising powder, (ii) optionally shaping said powder portion into a powder aggregate, and (iii) applying sufficient electromagnetic energy (EM energy) to said powder portion or said powder aggregate to transform said powder portion or... Agent:

20110070288 - Composite layered hemostasis device: The present invention is directed to a hemostatic composite structure having a bioabsorbable fabric or non-woven substrate having at least two major oppositely facing surface areas and a continuous non-porous polymer-based film that is laminated on one major surface of said substrate. The bioabsorbable fabric substrate can be an oxidized... Agent:

20110070289 - Adaptable modified virus vector to deliver modified messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases: Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver modified messenger RNA molecules to target cells... Agent:

20110070298 - Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance: The invention provides a composition comprising: an antigen; liposomes; a polyI:C polynucleotide; and a carrier comprising a continuous phase of a hydrophobic substance. Methods for making and using the compositions are also provided.... Agent: Immunovaccine Technologies Inc.

20110070291 - Food or beverage composition fortified with thyronamines and/or thyronamine precursors: Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing T2, T1AM, and/or T0AM in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage... Agent: T*amine, LLC.

20110070297 - Glucokinase activators: o

20110070294 - Methods for the administration of drugs using liposomes: Provided herein are methods for the administration of drugs using liposomes. In particular, provided herein is the use of liposomes as diluents for lyophilized or liquid drugs to deliver the drug safely, reduce the toxicity of the drug or the excipients used to solubilize or stabilize the drug.... Agent:

20110070292 - Methods for the preparation of liposomes: Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the... Agent:

20110070293 - Methods for the preparation of liposomes comprising docetaxel: Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.... Agent:

20110070295 - Methods for the preparation of liposomes comprising docetaxel: Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.... Agent:

20110070296 - Topical compositions and methods for utilizing peptides containing lipid-modified cysteine-containing peptides: Described are compositions for topical application to keratinous tissues or substrates such as skin, or mucosal surfaces. The composition may be used to treat a skin condition or disease. The composition comprises at least one polypeptide and/or lipidated peptide and a carrier.... Agent: Signum Biosciences, Inc.

20110070290 - Vaccine composition containing synthetic adjuvant: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from... Agent: Infectious Disease Research Institute

20110070299 - Delayed release pharmaceutical composition of duloxetine: A pharmaceutical composition comprising duloxetine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient(s) characterised in that the duloxetine has a D90 particle size of 2 to 40 μm.... Agent: Alphapharm Pty Ltd.

20110070300 - Extended release dosage forms of metoprolol: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.... Agent:

20110070301 - Orally transformable tablets: The present invention features a tablet including one or more pharmaceutically active agent(s), one or more thickeners, and one or more binder(s), wherein the tablet includes at least 200 mg of the pharmaceutically active agent(s) and the tablet has been fused with the binder(s) such that the tablet (i) has... Agent:

20110070303 - Novel dosage formulation: wherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to... Agent:

20110070302 - Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release: i) 55 to 92% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of 80 to 98% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from C1... Agent: Evonik Roehm Gmbh

20110070304 - Manufacture of tablet having immediate release region and sustained release region: In one aspect, the present invention features a process for making a tablet including a pharmaceutically active agent wherein the tablet has both an immediate release region and a modified release region. The method includes the steps of: (a) forming a tablet shape including a powder blend containing a pharmaceutically... Agent:

20110070305 - Sustained release pharmaceutical composition containing mebicar: The invention relates to a sustained release pharmaceutical composition, containing mebicar, for the treatment of anxiety, depression and other psychiatric and neurological disorders.... Agent: Alpharx Inc.

20110070306 - Antimicrobial nanoemulsion compositions and methods: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present... Agent:

20110070307 - Tissue regeneration: A method including positioning a delivery device at a location in a vessel within a mammalian body, introducing a first treatment agent including a cellular component through the delivery device, and introducing a different second treatment agent disposed in a carrier through the delivery device. A method including identifying an... Agent:

20110070308 - Bed bug insecticide: The insecticide comprises an insecticide particularly for killing bed bugs comprising nanospheres and primary ingredients of Organic Andirobia, Orange, Citronella, Organic Neem and Australian Myrtle oils. The insecticide can further comprise Isopropyl Alcohol as a carrier, Phenoxyethanol, Lavandox and Leucojum Aestivum Bulb Extrac.... Agent:

20110070309 - Pharmaceutical formulation comprising a water-insoluble active agent: A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second... Agent: Novartis Pharma Ag

20110070310 - Topical ophthalmic pharmaceutical formulation of (2s,3s,4r)-n''-cyano-n-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2h-benzopyran-4-yl)-n'-benzylguanidine: A topical ophthalmic pharmaceutical formulation may include particles of the compound (2S,3S,4R)—N″-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N′-benzylguanidine suspended in a solution comprising monobasic sodium phosphate monohydrate, disodium phosphate heptahydrate, edetate disodium, benzalkonium chloride, sodium chloride, polysorbate 80, and water. A method of treating glaucoma may include topically applying to the eye of a patient in... Agent: Mesh Therapeutics, LLC

20110070311 - Producing a sustained-release preparation: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.... Agent: Takeda Pharmaceutical Company Limited

20110070312 - Bone matrix compositions and methods: Methods for demineralizing bone are provided. In some embodiments, the methods include demineralizing the bone in a demineralization medium and separating the bone into particles during demineralization. In other embodiments, the methods include placing the bone in a demineralization medium and treating the demineralization medium while the bone is in... Agent:

20110070313 - Methods of inducing cell differentiation with placental extracts: Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce... Agent: Medistem Laboratories, Inc.

20110070314 - Methods for treating brain tumors: The present invention relates to methods treating brain tumors comprising administering a subject in need thereof a therapeutically effective amount of sodium meta arsenite, alone or in combination with another anti-brain tumor medicament.... Agent:

20110070315 - Composition for the treatment of hair loss and baldness: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal... Agent:

20110070316 - Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof: The present invention relates to compositions comprising quaternary ammonium compounds and essential oils or individual constituents thereof which exhibit enhanced antimicrobial effects. Such combinations may be comprised in lotions, gels, creams, soaps, etc. for application to skin or mucous membranes. The invention is based, at least in part, on the... Agent:

20110070317 - Pyrrolopyridines as kinase inhibitors: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Array Biopharma Inc.

20110070318 - skin dressings: A skin dressing is provided comprising a first component comprising a source of protons, a second component comprising a nitrite salt, the dressing comprising a non-thiol reductant, such that, when the first and second components are brought together and applied to a skin site the nitrite reacts to generate nitric... Agent: Insense Limited

20110070319 - Bifeprunox doses for treating schizophrenia: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation... Agent: Solvay Pharmaceuticals, B.v.

20110070320 - Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration: The present invention discloses a composition comprising a ginseng product, a mucoadhesive and a mucosa penetration enhancer in an aqueous biodegradable block copolymer solution consisting of a 3-arm polyethylene glycol (PEG) and 3 polyesters chains, each of which extends on each of the arm of the 3-arm PEG. The invention... Agent:

20110070321 - Method and composition for cutaneous treatment of herpes simplex infections: A method for cutaneous treatment of Herpes simplex infections by applying topically to the area of outbreak a composition comprising at least 1% by weight D-Lenolate® olive leaf extract. A composition for treatment is also disclosed, containing, by weight, at least 1% D-Lenolate® olive leaf extract, 1-3% neem, 0.05-1% aloe... Agent: East Park Research, Inc.

20110070322 - Pesticidal compositions containing rosemary oil and wintergreen oil: Pesticidal compositions containing rosemary oil and/or wintergreen oil and methods for using same are disclosed.... Agent: Ecosmart Technologies, Inc.

20110070323 - Pediculicide compositions: A non-toxic, highly effective composition for the elimination of lice and their eggs is provided. The composition contains natural products, namely plant oils, beside harmless cosmetic additives.... Agent: Fischer Pharmaceuticals Ltd.

20110064650 - Microorganisms for preventing and treating neoplasms accompanying cellular therapy: Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of... Agent:

20110064652 - Nanoparticles for targeted delivery of active agents to the lung: The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion... Agent:

20110064651 - Recombinant nucleotide sequence, cell or vector containing the same and method for using cell containing the same to encode anti-polyethylene glycol monoclonal antibodies: The invention provides a recombinant nucleotide sequence, including the sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, wherein the recombinant nucleotide sequence encodes an anti-polyethylene glycol recombinant single chain membrane antibody.... Agent: Kaohsiung Medical University

20110064653 - Class i anti-cea antibodies and uses thereof: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR... Agent: Immunomedics, Inc.

20110064654 - Prostate cancer diagnosis and treatment: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting,... Agent: Proscan Rx Pharma Inc.

20110064655 - Biomarkers for depression: Differential expression of nucleic acids in the brains of subjects suffering from late-onset depression has been demonstrated. The invention provides methods useful in the determination of late-onset depression. Also provided by the present invention is a screening method for the identification of compounds for treatment, prevention or diagnosis of late-onset... Agent:

20110064656 - Methods of determining renal function using technetium-99m tricarbonyl-nitrilotriacetic acid: This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer 99mTc(CO)3(NTA) (technetium-99m tricarbonyl-nitrilotriacetic acid). The disclosure encompasses methods of imaging the kidneys and measuring effective renal plasma flow (ERPF) in an animal or human subject using renal scintigraphy, comprising administering to an... Agent: Emory University

20110064659 - Glutamine biomarkers for depression: Differential expression of nucleic acids in the brains of subjects suffering from late-onset depression has been demonstrated. The invention provides methods useful in the determination of late-onset depression. Also provided by the present invention is a screening method for the identification of compounds for treatment, prevention or diagnosis of late-onset... Agent:

20110064657 - Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated... Agent: The Johns Hopkins University

20110064658 - Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors: RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.... Agent:

20110064660 - Deuterated alkyl phospholipid compounds, compositions, and methods of use: The invention generally relates to novel deuterated phospholipid compounds, compositions comprising these compounds, and their use in a variety of cancer therapy and diagnostic applications.... Agent:

20110064661 - Non-radioactive phospholipid compounds, compositions, and methods of use: The present invention provides phospholipid ether and alkyl phospholipid compounds and their combinations with other cancer therapy agents. More specifically, the invention relates to the use of phospholipid ether compounds comprising a “cold” isotope of iodine, e.g. 127I, or H, for treating cancer and combinations of phospholipid compounds comprising radioactive... Agent:

20110064662 - Kit for producing molecular probe for pet screening for drug discovery: Disclosed is a kit for use in the production of a molecular probe for PET drug screening for the purpose of producing a compound containing a short-lived radionuclide for PET applications. Specifically disclosed is a kit comprising a compound represented by the formula (I), (II) or (III) or a salt... Agent: Hamamatsu Photonics K.k.

20110064667 - Azide modified proteins: The present invention describes the modification of polypeptides, more particularly channel proteins with a thiol reactive agent so as to introduce an azide group. The present invention further describes vesicles comprising channel proteins modified according to the invention, which upon reaction with a phosphine open up thereby releasing the content... Agent: Koninklijke Philips Electronics N.v.

20110064663 - Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use: The invention relates generally to beta (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for synthesizing oligosaccharides using the beta (1,4)-galactosyltransferase I mutants and to using the beta (1,4)-galactosyltransferase I mutants to conjugate agents, such as therapeutic... Agent: Secretary, Department Of Health And Human Services

20110064666 - Compound: wherein, A is a single-chain antibody moiety, which is a polypeptide including an antigen-binding site; L is a linker moiety, which is a polypeptide including a protease cleavage site; Y is a peptide moiety, which including 0 or more amino acids connecting the linker moiety L with the single-chain antibody... Agent: Canon Kabushiki Kaisha

20110064665 - Diagnostic and therapeutic nanoparticles: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or... Agent: University Of Louisville Research Foundation, Inc.

20110064664 - Methods and compositions involving chitosan nanoparticles: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent... Agent: The Board Of Regents Of The University Of Texas System

20110064672 - Articles and compositions for enhancing sports scores: Methods and compositions for enhancing the score of an individual in a sport activity are disclosed.... Agent:

20110064668 - J-superfamily conotoxin peptides: The invention relates to relatively short peptides (termed J-Superfamily conotoxin peptides, J-conotoxins or J-conotoxin peptides herein), about 25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The... Agent: Max-planck Society

20110064670 - Method to identify a patient with an increased likelihood of responding to an anti-cancer agent: The invention provides methods for identifying patients having an increased likelihood of responding to an anti-cancer agent or an increased likelihood of undergoing metastasis. The invention also provides methods for monitoring a patients' response to an anti-cancer agent. The invention also provides kits and articles of manufacture for use in... Agent: Genentech, Inc.

20110064671 - Modulation of blood brain barrier permeability: The present invention relates to a method of increasing blood brain barrier permeability in a subject. This method involves selecting a subject who would benefit from increased blood brain barrier permeability and subjecting the selected subject to a treatment. That treatment increases adenosine level and/or bioavailability, modulates adenosine receptors, and/or... Agent: Cornell University

20110064669 - Use of galanin in a method of treating neurodegenerative diseases or conditions: The present invention relates generally to a method for the treatment and prophylaxis of neurodegenerative diseases and conditions. More particularly, the present invention contemplates the treatment or prophylaxis of neurological conditions involving oligodendrocyte cytotoxicity or cell cycle arrest, demyelination and/or axonal or neuronal degeneration. Agents, medicaments and pharmaceutical compositions useful... Agent: Howard Florey Institute Of Experimental Physiology And Medicine

20110064674 - Luminescent multimodal nanoparticle probe system and method of manufacture thereof: A method of manufacture of a luminescent nanoparticle probe system includes forming a bismuth sulfide core; and coating the bismuth sulfide core with a shell.... Agent: Carnegie Mellon University

20110064673 - New l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them: The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof.... Agent:

20110064675 - Elemental iron nanoparticles: Synthesis of iron nanoparticles with a substantially unoxidized iron core and a biocompatible coating is described. The nanoparticles are formed by reacting an iron salt solution with a reducing agent in a substantially oxygen-free environment and exposing the formed iron particles to a biocompatible coating agent in a substantially oxygen-free... Agent: University Of Delaware

20110064676 - Diagnostic and therapeutic nanoparticles: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or... Agent: University Of Louisville Research Foundation, Inc.

20110064677 - Lipoxin analogs and methods for the treatment of periodontal disease: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms... Agent: University Of Southern California

20110064678 - Styling agents giving a high degree of hold: An agent for the temporary deformation of keratinic fibers comprises, in a cosmetically acceptable carrier, a) at least one copolymer A formed from: at least one monomer A1 selected from acrylic acid, methacrylic acid, acrylic acid alkyl esters, and methacrylic acid alkyl esters; at least one monomer A2 selected from... Agent: Henkel Ag & Co. Kgaa

20110064679 - Oxaloacetic acid and salts of oxaloacetic acid as a flavor, an acidizing and a preservative agents and methods for preparing and using same: Provided herein is a method for flavoring an ingestible composition with an organoleptically effective amount of the flavoring agent. The flavoring agent may be used in a wide variety of ingestible vehicles such as chewing gum compositions, hard and soft confections, toothpaste, dairy products, beverage products including juice drinks and... Agent:

20110064680 - Naturally derived waterproofing agents for aqueous-based personal care products: Personal care compositions such as sunscreens, color make-up, lotions and creams which contain an amount of a hydrogenated rosin or resin which provides increased resistance to removal by water of such personal care compositions.... Agent: Pinova, Inc.

20110064681 - Polyurethanes as rheological modifying means for cosmetic preparations: The present invention relates to cosmetic preparations comprising novel polyurethanes or mixtures thereof as means for modifying rheological properties.... Agent: Basf Se

20110064682 - Cosmetic composition comprising a stem-cell culture fluid, and a production method therefor: The present invention relates to a method of improving wrinkle, whitening or anti-oxidation of a skin, and more specifically, to a method of improving wrinkle, whitening or anti-oxidation of a skin, comprising applying a cosmetic composition comprising a stem cell culture fluid as an active ingredient to the skin. Further,... Agent: Han Cell

20110064683 - Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions: Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.... Agent: Technology Corporation)

20110064685 - Silicone replacements for personal care compositions: Described are personal care compositions, comprising an aqueous dispersion comprising a metallocene catalyzed polyolefin and an ethylene acrylic acid copolymer; a cationic polymer; and a least one cosmetically acceptable surfactant, emollient, or cosmetic active, provided that the personal care composition contains less than 0.09 wt % of silicone, and preferably... Agent: Union Carbide Chemicals & Plastics Technology LLC

20110064686 - Cationic polymers as conditioning agents: The present invention provides personal care compositions comprising a cosmetically acceptable, cationically modified ethylene acrylic acid polymer that has a net cationic charge at pH 6, and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.... Agent: Dow Global Technologies Inc.

20110064687 - Mono-, di- and polyol phosphate esters in personal care formulations: A hydrophilized personal care formulation, which can be in the form of a hand or body soap (liquid or bar), lipstick, body wash, makeup remover, skin cleaner, hair conditioner, skin or hair moisturizer. The formulation employs an organophosphorus material or a mixture of an organophosphorus material, for example, mono-, di-,... Agent: Rhodia Inc.

20110064688 - Silicone deposition aid for personal care compositions: Described are personal care compositions, comprising an aqueous dispersion comprising silicone and an ethylene acrylic acid copolymer; and at least one cosmetically acceptable surfactant, emollient, or cosmetic active.... Agent: Dow Global Technologies Inc.

20110064684 - Method of chemically modifying the internal region of a hair shaft: A method of chemically modifying the internal region of a hair shaft, comprising the steps of: providing and applying to hair a treatment composition comprising from 0.1% to 20% of an ethylenic monomer by weight of the total composition, an initiator and a dermatologically acceptable carrier; and exposing the hair... Agent:

20110064692 - Human bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression.... Agent: Bone Therapeutics S.a.

20110064689 - In situ immunization: The arming of activated T cells (ATC) with BiAbs can overcome major barriers for successful adoptive immunotherapy. The BiAb approach takes the advantage of the targeting specificity of monoclonal antibodies and the cytotoxic capacity of T cells to lyse tumors. Arming of ATC with BiAb makes every T cell an... Agent: Roger Williams Medical Center

20110064691 - Method to enhance hematopoiesis: The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF... Agent: S-cell Biosciences, Inc.

20110064690 - Pegylated interleukin-10: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus... Agent: Schering Corporation

20110064694 - Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues: The present invention relates to porphyrin analogues, their use in pharmaceutical compositions alone, or combination with other agents and in the treatment and/or prophylaxis of flaviviridae viral infections, especially hepatitis C viral infection, and secondary disease states and/or conditions associated with same.... Agent: Yale University

20110064693 - Antiviral drugs for treatment of arenavirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by... Agent:

20110064695 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent:

20110064696 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent:

20110064697 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent:

20110064698 - Hepatitis c virus inhibitors: i

20110064706 - Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend: A method and composition prevents, controls and ameliorates urinary tract infections caused by E. coli by administering a therapeutically effective amount of a human dietary supplement composition comprising a cranberry derivative or proanthocyanidin containing concentrate, D-mannose and a proprietary probiotic blend. The cranberry derivative or proanthocyanidin containing concentrate comprises from... Agent: U.s. Nutraceuticals, LLC D/b/a Valensa International

20110064707 - Probiotics to improve gut microbiota: The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants without siblings.... Agent: Nestec S.a.

20110064708 - Methods and compositions for the dietary management of autoimmune disorders: The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus Bacillus, in treating digestive-related immune disorders by downregulating of cytokines and by inhibiting pathogenic or deleterious microorganisms in the gastrointestinal tract. Specific formulations of Bacillus coagulans for various immune disorders are elaborated.... Agent: Ganeden Biotech Inc.

20110064710 - Novel bacillus thuringiensis isolate: A novel bacterial strain of Bacillus thuringiensis, VBTS 2528, is described. This strain comprises genes encoding Cry1Ac, Cry 1Ca, and Cry2Aa endotoxin proteins. The invention further relates to an insecticidal composition comprising a mixture of VBTS 2528 and to methods for controlling insect pests utilizing VBTS 2528.... Agent:

20110064699 - Reducing conjugative plasmids in bacteria: The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding... Agent: Gangagen, Inc.

20110064703 - Bone substitute compositions, methods of preparation and clinical applications: The present invention relates to bone substitute compositions and methods of their preparation, and their use in a wide variety of clinical applications. The compositions include calcium phosphate, acidic calcium salt, basic calcium salt, sodium hydrogen phosphate and porogen. The compositions further include a mixing liquid. The compositions can optionally... Agent:

20110064705 - Hemangio colony forming cells and non-engrafting hemangio cells: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial... Agent: Advanced Cell Technology, Inc.

20110064702 - Methods and kits for enhancing cell survival, stimulating cell proliferation, treating diabetic patients, and/or reinnervation: Methods for enhancing beta cell survival and/or for stimulating beta cell proliferation, comprise co-transplanting pancreatic islets, beta cells, and/or stem cells which can generate beta cells, with (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor... Agent:

20110064700 - Neural stem cells: The invention provides compositions and methods for obtaining neural stem cells from post-natal subjects and their use in treating neurological disorders.... Agent: President And Fellows Of Harvard College

20110064701 - Pluripotent embryonic-like stem cells, compositions, methods and uses thereof: The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present... Agent: Abt Holding Company

20110064704 - Ship-deficiency to increase megakaryocyte and platelet production: A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.... Agent: University Of South Florida

20110064709 - Use of ecdi-fixed cell tolerance as a method for preventing allograft rejection: The present invention provides methods, systems, and compositions for inducing donor-specific tolerance. In particular, the present invention provides methods of administering ECDI-treated cells before, during, and/or after administration of donor transplant cells or a donor allograft in order to induce tolerance for the cells and/or allograft in a recipient.... Agent: Northwestern University

20110064711 - Compositions containing coenzyme q-10 and an antioxidant: The invention describes compositions of a reduced form of coenzyme Q-10 (CoQ10) or CoQ10 or both and an antioxidant that is an anthocyanin extract, a melanin or a compound having at least one thiol (—SH) group.... Agent:

20110064712 - Dietary supplement compositions and methods of making and using the same: Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed.... Agent:

20110064714 - Factor viia-polysialic acid conjugate having prolonged in vivo half-life: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal,... Agent: Baxter International Inc.

20110064713 - Methods of treating cancer using opioid retargeted endopepidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.

20110064715 - Methods for determining oligosaccharide binding: The invention relates to methods for detecting and characterizing enzymatic modifications of oligosaccharides, such as heparan sulfate, and their interaction with binding partners, such as proteins, using an oligosaccharide-binding partner binding assay, such as a gel mobility shift assay. The instant invention relates to a rapid, convenient, sensitive and inexpensive... Agent:

20110064717 - Homing endonuclease genes and their targets: The invention provides pharmaceutical composition having as an active ingredient either a homing endonuclease (HE) capable of cleaving a non-native target nucleotide sequence in a genome or a nucleotide sequence encoding for a HE capable of cleaving a target site in a non-native genome. The invention also provides uses for... Agent: Ramot At Tel-aviv University Ltd.

20110064716 - Materials and methods for treating or preventing organophosphate exposure associated damage: A method of treating or preventing organophosphate exposure associated damage in a subject in need thereof is provided. The method comprising providing the subject with a therapeutically effective amount of AChE-R to thereby treat the organophosphate exposure associated damage in the subject.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20110064718 - Pesticidal and antiparasitic compositions: This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the... Agent: Centro De Ingenieria Genetica Y Biotecnologia

20110064719 - Hydrophobic interaction chromatography purification of factor vii polypeptides: The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern.... Agent: Novo Nordisk A/s

20110064720 - Dietary supplement compositions and methods of making and using the same: Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed.... Agent:

20110064721 - Cathepsin-d neuroprotection: Provided herein are methods and compositions for promoting neuroprotection in a subject and for treating a neural disorder associated with protein aggregation comprising administering to the subject an agent that increases expression or activity of cathepsin-D. Also provided are methods of screening for agents that increase expression or activity of... Agent: The University Of Alabama

20110064723 - Formulation for room temperature stabilization of a live attenuated bacterial vaccine: This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are provided that stabilize the viability of live bacteria and live virus vaccines at room temperature.... Agent: Aridis Pharmaceuticals

20110064724 - Methods for identifying compounds for the treatment of type 1 diabetes: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit... Agent: Biocrine Ab

20110064722 - Modulators of alpha-synuclein toxicity: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease.... Agent: Whitehead Institute For Miomedical Reasearch

20110064726 - Anti ige antibodies: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.... Agent: Amgen Fremont Inc.

20110064725 - High affinity, anti-human ige antibodies: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These... Agent: Tanox, Inc.

20110064729 - Administration of agents for the treatment of inflammation: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the... Agent: Elan Pharmaceuticals, Inc.

20110064733 - Ca6 antigen-specific cytotoxic conjugate and methods of using the same: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the... Agent: Immunogen, Inc.

20110064737 - Erbb antagonists for pain therapy: The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.... Agent:

20110064728 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent:

20110064727 - Immunoglobulin variants outside the fc region: The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application.... Agent: Xencor, Inc.

20110064730 - Method of modulating angiogenesis: A method for the identification of a nucleic acid molecule differentially expressed in an in vitro model of a biological system, comprising the steps of: (1) harvesting cells from the model system at predetermined time points; (2) obtaining total RNA from the cells harvested at each time point; (3) preparing... Agent:

20110064732 - Methods and compositions for diagnostic use in cancer patients: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.... Agent:

20110064735 - Methods for treating lymphomas in certain patient populations and screening patients for said therapy: Methods for predicting a response of a patient having a lymphoma to a therapy regimen of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione using prognostic factors of a patient's disease burden, absolute lymphocyte count or time since last rituximab therapy are disclosed. Specific methods of treating a lymphoma encompass the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione to a patient... Agent: Celgene Corporation

20110064734 - Prevention and treatment of amyloidogenic disease: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which... Agent: Elan Pharmaceuticals, Inc.

20110064736 - Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2: The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits... Agent:

20110064731 - Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis: The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.... Agent: National Cheng Kung University

20110064738 - Human anti-vegf polyclonal antibodies and uses thereof: This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins.... Agent:

20110064739 - Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung: The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e.... Agent:

20110064740 - Antigen binding proteins: The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterised by elevated β-amyloid levels or β-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and β-amyloid dependent cataract formation, with antigen binding proteins that bind β-amyloid peptide and in particular... Agent: Glaxo Group Limited

20110064742 - Somatostatin receptor antagonists and glucose control or hypoglycemia: The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.... Agent:

20110064741 - Stable amyloid beta monomers and oligomers: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild... Agent: Mivac Development Aktiebolag

20110064743 - Human anti-cancer antibodies: The present invention provides novel human anti-cancer antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of cancer.... Agent:

20110064744 - Prevention and treatment of pain using antibodies to lysophosphatidic acid: Methods for preventing or treating pain are provided, comprising administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA.... Agent:

20110064745 - Therapeutic antibodies, antibody fragments and antibody conjugates: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment... Agent:

20110064746 - Treatment of drug-related side effect and tissue damage by targeting the cd24-hmgb1-siglec10 axis: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv... Agent:

20110064749 - Compositions comprising immunoreactive reagents and saponins, and methods of use thereof: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of... Agent: Csl Limited

20110064747 - Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10): Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of... Agent:

20110064748 - Pharmaceutical combination and method for treating tumor: t

20110064753 - Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions... Agent: Seattle Genetics, Inc.

20110064752 - Extracellular targeted drug conjugates: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the... Agent: Centrose, LLC

20110064754 - Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines: The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and... Agent: Center For Molecular Medicine And Immunology

20110064750 - Method and kit for treating nicotine addiction: Described are methods and kits related to treating nicotine addiction and increasing the likelihood of nicotine abstinence. Methods and kits for reestablishing nicotine abstinence after a relapse to nicotine use are also described.... Agent: Nabi Biopharmaceuticals

20110064751 - Targeted immunoconjugates: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid... Agent: Roche Glycart Ag

20110064755 - Methods for producing block copolymer/amphiphilic particles: The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, compositions comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell... Agent: Vical Incorporated

20110064756 - Novel sequences of brachyspira, immunogenic compounds, methods for preparation and use thereof: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of... Agent: Spirogene Pty Ltd

20110064758 - Infectious clones of torque teno virus: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention... Agent: Pfizer Inc.

20110064759 - Method for the identification of extracellular domains of epstein barr virus (ebv) tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith: Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the cuter cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of... Agent: Cyto-barr B.v.

20110064757 - Nucleic acid molecules and polypeptides for immune modulation: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and... Agent: Viron Therapeutics, Inc.

20110064760 - Polypeptides comprising epitopes of hiv gp41 and methods of use: An isolated polypeptide that has an amino acid sequence that is substantially homologous to consecutive amino acids of a c-terminal portion of the membrane proximal external region (MPER) of gp41 includes an immunogenic epitope reactive with at least one anti-HIV antibody.... Agent:

20110064761 - Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of... Agent: Spirogene Pty Ltd

20110064762 - Protein a compositions and methods of use: Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA),... Agent: Protalex, Inc.

20110064764 - Attenuated live triple g protein recombinant rabies virus vaccine for pre- and post-exposure prophylaxis of rabies: The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic... Agent: Thomas Jefferson University

20110064763 - Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein: Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the... Agent: Immune Design Corp.

20110064766 - Attenuated vaccine against fish pathogen francisella sp.: An attenuated bacteria has been made by an insertion mutation in the iglC gene of Francisella asiatica, by allelic exchange. The attenuated strain proved to be an effective vaccine by providing protection against an infection of F. asiatica in tilapia, and is believed would at least partially immunize fish from... Agent:

20110064765 - Pcv-2 vaccine:

20110064767 - Cdna construct of salmonidae alphavirus: The invention concerns recombinant DNA's comprising c NDA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.... Agent: Institut National De La Recherche Agronomique

20110064768 - Immunogenic compositions: An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.... Agent:

20110064769 - Vv promoter-driven overexpression of recombinant antigens: The present invention is directed to the use of a pharmaceutical composition comprising a vaccinia virus (VV) based vector construct under the control of a strong VV specific promoter. The present invention is in particular directed to the use of this pharmaceutical composition for the treatment of infectious diseases, chronic... Agent: Helmholtz-zentrum Fur Infektionsforschung Gmbh

20110064770 - Immunization of an individual against carcinomas and the preliminary stages thereof: The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle... Agent:

20110064771 - Plant extracts and uses thereof: Plant extracts obtainable by extracting various plant materials with an alkaline agent, methods for preparing such extracts, compositions comprising such extracts, and methods for using the extracts or compositions thereof are described.... Agent: Tampa Bay Research Institute Inc.

20110064772 - Viral adjuvants: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or... Agent: University Of North Carolina At Chapel Hill

20110064773 - pharmaceutical compositions comprising a thyroid hormon and their therapeutic use: The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3′,5′,3-triiodothyronine (rT3), a rT3 derived hormone, or a precursor of rT3, such as T4 in association with a molecule susceptible to promote the formation of rT3, in association with a pharmaceutically acceptable... Agent: Centre National De La Recherche Scientifique

20110064774 - Bulking agent: The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, aneurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection... Agent: Boston Scientific Scimed, Inc.

20110064776 - Dental composition containing organic nanotube: e

20110064775 - Metallo-organic system for the encapsulation and release of compounds of interest, method for obtaining same and uses thereof: The present invention discloses a metallo-organic system that includes: a metal ion salt or complex; at least one organic ligand; and a substance of interest to be encapsulated, belonging to the group comprising a biological entity, a drug, a vaccine, a diagnostic contrast agent, a marker, an organic compound, an... Agent: Institut Catal&#xc1 De Nanotecnologia

20110064778 - Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients: The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there is... Agent:

20110064777 - Live lactobacillus soap and method for delivering lactobacillus to skin tissue: Microbiotic Soap made with the addition of Lactobacillus or other natural bacteria found in yoghurt. The intention of the invention being to deliver live Lactobacillus and/or other bacteria on to the skin via Microbiotic Soap. Special structures ‘Gel Lactowich’ and ‘Gel Lactospheres’ allow Lactobacillus and other natural bacteria to continue... Agent:

20110064779 - Pearlescent pigments based on fine and thin substrates: Pearlescent pigments including a largely transparent platelet-shaped substrate having a density ρS and at least one optically active coating having a density ρM, the substrate having an average size d50 of 3 to 8 μm and an average height hS of 40 to 110 nm. The disclosure further relates to... Agent:

20110064780 - Polymeric pheromone formulation and method of use to calm stress-related behavior in mammals over an extended period of time: The present invention is directed to a polymeric formulation for controlling animal behavior comprising a low melting point polymer or copolymer, an unsaturated long chain fatty alcohol, and an animal-appeasing pheromone to produce a solid slow release generator of the pheromone. The system is useful for making animal collars and... Agent:

20110064782 - Methods and compositions for tissue regeneration: A decellularised collagen-containing matrix for guided tissue regeneration, wherein the matrix is derived from a natural tissue material and is substantially free of non-fibrous tissue proteins, cellular elements and lipids or lipid residues and wherein the matrix displays the original collagen fibre architecture and molecular ultrastructure of the natural tissue... Agent:

20110064781 - Novel heparin entities and methods of use: The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.... Agent:

20110064783 - Flavor impregnation of a chewing gum core: A method of adding flavor to a chewing gum core of a chewing gum, the chewing gum including active pharmaceutical ingredients, the method of adding flavor to a chewing gum core including the steps of: providing a chewing gum core including gum base, impregnating the chewing gum core by adding... Agent:

20110064784 - Method for producing a three-dimensional macroporous filament construct based on phase inversion and construct thereby obtained: The present invention relates to a method for producing a three-dimensional macroporous filament construct comprising interconnected microporous filaments showing a suitable surface roughness and microporosity. The method comprises the steps of: a) preparing a suspension comprising particles of a predetermined material, a liquid solvent, one or more binders and optionally... Agent: Vito Nv

20110064785 - Nanostructure-enhanced platelet binding and hemostatic structures: Methods, systems, and apparatuses for nanomaterial-enhanced platelet binding and hemostatic medical devices are provided. Hemostatic materials and structures are provided that induce platelet binding, including platelet binding and the coagulation of blood at a wound/opening caused by trauma, a surgical procedure, ulceration, or other cause. Example embodiments include platelet binding... Agent: Nanosys, Inc.

20110064786 - Novel use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells: De-differentiation protocols are described herein for generating progenitor cells from adult connective tissue, in particular adult human fibroblasts. The de-differentiation protocols described herein comprise culturing the differentiated cells with an amount of FGF2 to de-differentiate the cells. These de-differentiated cells may then be cultured and used for experimentation, amplification and... Agent:

20110064787 - Detoxifying patch: A detoxifying patch is disclosed that is preferably applied to the soles of the feet as a therapeutic treatment to remove toxins from the body and increase blood circulation. The patch includes a pouch and a backing with an optional foil backing. The pouch contains various ingredients including mandarin wood... Agent:

20110064788 - Pharmaceutical compositions for treatment of addiction: The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and either methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl... Agent: Syntropharma Limited

20110064790 - Adaptable modified virus vector to deliver ribosomal ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases: Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver ribosomal RNA molecules to target cells in... Agent:

20110064796 - Concentrated, inhalable antibiotic formulation: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.... Agent: Aradigm Corporation

20110064789 - Docosahexanoic acid as inhibitor of h. pylori: The present invention concerns a method for preventing, modulating or curing in a mammal, the infections with Helicobacter pylori or the symptoms associated with H. pylori infection(s) or related diseases, and/or improving the clinical condition of a mammal infected with H. pylori, or affected by a related disease, comprising administering... Agent:

20110064794 - Drug delivery system, its preparation process and use: A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and... Agent: Hangzhou Yuhong Pharmaceutical Science & Technology Co., Ltd.

20110064793 - Inhibitors of hiv replication and method of treatment of hiv infections: The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions... Agent: Centre National De La Recherche Scientifique (c.n.r.s.)

20110064792 - Method for opening tight junctions: The present invention is directed to a method and use of RNA interference (RNAi) for the transient, reversible and controlled opening of the tight junctions of the blood brain barrier and/or the blood retinal barrier. This method may be used in the treatment of many diseases and disorders which require... Agent:

20110064791 - Self forming, thermodynamically stable liposomes and their applications: Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.... Agent: Biozone Laboratories, Inc., A California Corporation

20110064795 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers: The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty... Agent: Ac Immune Sa

20110064797 - Capsule of thermogenic cells for treating a metabolic disease: Described herein are methods and devices for treating a metabolic disease that involve implanting a micro-device into a tissue of a subject having a metabolic disease. The micro-device includes a plurality of thermogenic cells encapsulated in a biocompatible capsule. The capsule includes a core to accommodate the plurality of thermogenic... Agent: The Ohio State University

20110064798 - Suspension containing hydronium stabilized colloidal silicic acid nanoparticles, formulation obtained from the said dilutesuspension, powder obtained from the said de-hydrated suspension, compositions obtained from the said powder, preparation and use: The present invention relates to hydronium stabilized silicic acid nanoparticles, to the formulation obtained from the said diluted suspension, to the powder obtained from the said dehydrated suspension and to the preparation or dosage form obtained from the said suspension, formulation or powder, to their preparation and their use in... Agent: Jisbrey, S.a.

20110064800 - Nanoparticulate and controlled release compositions comprising cyclosporine: The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune... Agent:

20110064799 - Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency: Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.... Agent:

20110064801 - Pharmaceutical formulations containing an sglt2 inhibitor: m

20110064802 - Improved capsule with air-vents: The invention relates to a capsule comprising a hollow tubular body (2), a hollow cap (3) telescopically engageable on the body (2), the body (2) and the cap (3) defining an inner volume therebetween and being provided with complementary snap-fit means (12, 21) for locking the cap (3) on the... Agent: Pfizer Inc.

20110064803 - Nanoparticulate and controlled release compositions comprising vitamin k2: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to... Agent: Elan Pharma International Limited.

20110064804 - Methods and compositions for the treatment of cns-related conditions: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.... Agent: Adamas Pharmaceuticals, Inc.

20110064805 - Porous cellulose aggregate and molding composition thereof: A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm3/g, containing I-type crystals and having an average particle size of over 30 to 250 μm, a specific surface area of... Agent: Asahi Kasei Chemicals Corporation

20110064806 - Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same: The invention provides solid compositions comprising (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid (OC-1) or a salt thereof and methods of making and using those compositions. The invention also provides the monohydrochloride salt of (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid.... Agent: Transtech Pharma, Inc.

20110064807 - Extended release formulation of levetiracetam: An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of... Agent: Ucb Pharma S.a.

20110064808 - Extended release formulation of levetiracetam: The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible... Agent: Ucb Pharma S.a.

20110064809 - Scaffolds: The invention relates to methods of preparing tissue implants for use in the augmentation, repair and regeneration of tissues.... Agent:

20110064810 - Tissue engineering method for organ reconstruction using injectable matrix: The various embodiments herein relate to an injectable matrix used for regeneration, reconstruction, repair or replacement of organ or tissue. The injectable matrix consists of a synthetic and natural polymer, a stem cell niche and nanoparticles in the form of cups filled with growth factor and physiologic agent. The embodiments... Agent:

20110064816 - Atorvastatin compositions: Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration.... Agent: Dr. Reddy's Laboratories, Inc.

20110064812 - Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin: An oral solid dosage form containing nanoparticles is made by (a) reducing the particle size of at least one pharmaceutically active ingredient dispersed in a solution containing fish gelatin to form a nanosuspension and (b) freeze-drying the nanosuspension of step (a) to form the oral solid dosage form.... Agent:

20110064815 - Silicia for the inhinition of a protease: There is provided a silica for use to inhibit a protease. In particular there is provided a silica for treatment or prevention of a disease or condition associated with adverse protease activity or adverse proteolytic degradation within the gastrointestinal tract.... Agent:

20110064811 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.... Agent:

20110064814 - Stable pharmaceutical products: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.... Agent: Nycomed Gmbh

20110064813 - Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet: The invention relates to a compound and administration of the compound to mammals containing salsalate in a nanofied form to reduce inflammation. This compound and administration may be combined with caffeine, omega 3 fatty acids, sodium bicarbonate, and/or simvastatin to further benefit that administration.... Agent:

20110064817 - Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients: The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there is... Agent:

20110064819 - Encapsulation of biologically active agents: The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment.... Agent:

20110064818 - Pharmaceutical composition and a method for the production thereof: The invention relates to producing medicinal agents for treating diabetes. There is proposed a method for producing a pharmaceutical composition containing insulin on a polysaccharide carrier, which involves mixing initial ingredients, wherein there is provided, for mixing, supplying positively charged chitosan sol with pH of 3.5 to 4.5 and negatively... Agent:

20110064821 - Encapsulation of biologically active agents: The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles. Also provided are methods of delivery of proteins across the blood brain barrier in nanoparticles, and uses of such compositions in treatment.... Agent:

20110064820 - Pharmaceutical compositions comprising phosphate-binding polymer: The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion... Agent:

20110064822 - Biomaterial and preparation method thereof: A biomaterial prepared from a process comprising dehydrating the fish scales until the fish scales containing less than about 50% of water, and grinding the dehydrated fish scales into ground particles each having an average size of less than about 10,000 μm in diameter, wherein the ground particles contain a... Agent: Body Organ Biomedical Corp.

20110064823 - Transdermal delivery apparatus and method: An apparatus and method for applying a beneficial agent to the skin is disclosed in one embodiment of the invention as including first and second chemical reactants, each being compatible with the skin. The first and second chemical reactants react with one another to generate a beneficial agent and enhance... Agent:

20110064824 - Method for enriching water with oxygen by an electrolytic process, oxygen enriched water or beverage and uses thereof: The invention relates to a method for enriching water with oxygen by an electrolytic process, that comprises the following series of steps: the electrolysis of Cl− Br− ion-free water in an electrolysis cell in which the anode and the cathode are separated by a gas-tight membrane that is pervious to... Agent:

20110064825 - Method for preparing dispersions of precious metal nanoparticles and for isolating such nanoparticles from said dispersions: The present invention is directed to a method for preparing colloidal dispersions of precious metal nanoparticles selected from the group consisting of Pt, Au, Pd, Ag, Rh, Ru and mixtures or alloys thereof, and to a method for isolating such precious metal nanoparticles from these colloidal dispersions. The colloidal dispersions... Agent: Umicore Ag & Co. Kg

20110064826 - Composition for treating skin lesions: The present invention provides a composition for topical treatment of skin and mucosal membrane lesions comprising a synergistic combination of copper compound and hypericum perforatum extract.... Agent:

20110064827 - Active compound combinations: The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of... Agent: Bayer Cropscience Ag

20110064828 - Treatment of metastatic tumors and other conditions: The present invention generally relates to pharmacology and, in particular, to the treatment of tumors and other conditions. In some aspects, the invention is directed to the treatment of subjects having tumors or cancers that are metastatic. Surprisingly, it has been found that certain compositions comprising oxidized glutathione-based compounds are... Agent: The Wistar Institute

20110064829 - Persistent and fast acting antiseptics and disinfectants based on calcium fluoride: Antiseptic compounds that act as persistent and fast acting antiseptics and disinfectants. The base of these antiseptic actions is CaF2 as the persistent part, preventing the colonization of tissue and nonliving surfaces with microorganisms through the targeted on-demand release of fluorine ions. For fighting heavy contamination and invasion of transient... Agent:

20110064830 - Film-shaped preparation comprising oily substances for oral administration: Water-soluble, solid, film-shaped preparations comprising at least one film-forming polymer selected from the group consisting of the fully and partially hydrolyzed polyvinyl alcohols, and at least one water-insoluble, oily liquid which is incorporated into the film-forming polymer and amounts to at least 30 percent by weight, relative to the dry... Agent: Lts Lohmann Therapie-systeme Ag

20110064831 - Fungicidal compositions: The present invention relates to fungicidal compositions and particularly fungicidal compositions comprising anhydrous milk fat (AMF), soybean oil and/or coconut fat. The invention also relates to a fungicidal method employing a composition of the invention. The compositions and methods of the invention have applications in the management (prevention and control)... Agent: The Horticulture And Food Research Institute Of New Zealand Limited

20110064832 - Skin care formulations: Disclosed are compositions and methods for treating skin comprising a chemically compatible combination of skin active ingredients comprising palmitoyl tetrapeptide-7, methylsilanol mannuronate, and Lactobacillus ferment, a chemically compatible combination of skin active ingredients comprising plant extracts from Punica granatum, Castanea sativa, Gossypium hirsutum, and Euterpe oleracea, and a dermatologically acceptable... Agent: Mary Kay, Inc.

20110064833 - Synergistic herbal composition and process of preparation thereof: The present invention relates to a synergistic herbal composition for diabetes and related disorders comprising extracts of plant Eugenia of concentration ranging between 10-80% and plant Cinnamomum of concentration ranging between 10-80% optionally along with pharmaceutically acceptable excipients; a method of treating diabetes and related disorders in a subject in... Agent:

20110064834 - Novel pest repellant composition and method of use: The present disclosure relates generally to a novel pest repellant composition for use in repelling reptiles, rodents, birds, insects, and other unwanted pests. Advantageously, this pest repellant composition is safe, effective, economical to produce, and environmentally-friendly. It is used via spreading in an area of interest, for example. The novel... Agent:

20110064835 - Process for the preparation of active principles on thermal water and compositions comprising them: The invention relates to a process for the preparation of a cosmetic or dermatological active principle, comprising the culturing of at least one nonphoto-synthetic and nonfruiting filamentous bacterium on a medium comprising at least one nonsulphurous mineral and/or thermal water. It also relates to a cosmetic or dermatological composition comprising... Agent: L'oreal

20110059010 - Dual phase drug release system: The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure (I): wherein each occurrence of M is independently a modifier having a molecular weight ≦10 kDa; denotes direct of indirect attachment of M to linker LM; and each occurrence... Agent: The General Hospital Corporation

20110059013 - Anti-robo4 antibodies and uses therefor: The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.... Agent: Genentech, Inc.

20110059011 - Diagnosis and treatment of diseased and damaged tissue: The present invention relates to the diagnosis and treatment of leukemia and cardiovascular disease, as well as the detection of diseased and damaged tissue. More particularly, the present invention provides methods for targeting calcitonin receptor expressing cells for the diagnosis and treatment of leukemia or cardiovascular disease, and for stimulating... Agent:

20110059012 - Identification of cd8+ t cells that are cd161hi and/or il18r (alpha) hi and have rapid drug efflux capacity: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18Rα and the capacity to rapidly efflux the fluorescent dye Rh123.... Agent: Fred Hutchinson Cancer Research Center

20110059014 - Compounds and methods of making compounds: Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2′, 4′, and 11′, as well as uses for the compounds for imaging, and the like.... Agent:

20110059018 - Covalently binding imaging probes: b

20110059020 - Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same: To provide a liposome composition, which contains at least one liposome; gas entrapped in the liposome, and at least one metal oxide particle encapsulated in or adsorbed on the liposome, wherein the liposome composition satisfies a ratio B/A of 0.01 to 5, where A is a volume of the gas... Agent: Fukuoka University

20110059019 - Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors: This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, 5HT1A and 5-HT2A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.... Agent: Neurosearch A/s

20110059016 - Optical assay system with a multi-probe imaging array: The subject matter described herein relates to an optical assay system having a multi-probe imaging array that orients a plurality of probes with respect to one another and to a sample. According to one aspect, the subject matter described herein includes a multi-probe imaging array for contacting biological samples and... Agent:

20110059017 - Polymer coated sers nanotag: An encapsulated surface enhanced Raman scattering (SERS) tag. The tag includes a metal core and an encapsulant, typically a glass encapsulant. The encapsulant is further derivatized with a polymer.... Agent: Becton, Dickinson And Company

20110059015 - Vaccine: The application relates to antibodies and fragments capable of binding HIV-1 gp120 protein, nucleic acids encoding such proteins, to the use of such proteins to identify active compounds, and to the use of the compounds as vaccines.... Agent: Pharmacia Spain

20110059021 - Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli: A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (ΔSpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific... Agent: Juridical Foundation The Chemo-sero-therapeutic Research Institute

20110059025 - In vivo imaging: The present invention provides an imaging method for obtaining an image of a patient by means of a contrast agent wherein the method comprises subjecting the patient to an imaging method for which the contrast agent is suitable, wherein the contrast agent comprises: (a) a binding moiety; and (b) a... Agent: Iti Scotland Limited

20110059024 - Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same: To provide a liposome composition, which contains at least one liposome, gas entrapped in the liposome, and at least one fullerene encapsulated in or adsorbed on the liposome.... Agent: Fukuoka University

20110059023 - Narrowband imaging using near-infrared absorbing nanoparticles: Devices and methods are provided for image identification of contrast agents comprising nanopartiles. The imaging devices and methods may also be configured to identify target tissues from surrounding tissues such as disease conditions (e.g. cancer tumors) through narrow-band imaging of tissue. Contrast agents such as near-infrared absorbing nanoparticles may be... Agent:

20110059022 - Two photon tracer, method for the preparation thereof and the use thereof in screening anticancer agents: Disclosed herein are compounds useful as two-photon tracers. Also, methods are provided for visualizing intracellular glucose uptake, screening anticancer agents, and diagnosing cancer using the compounds. They exhibit preferential uptake by cancer cells, penetrability sufficient to allow bright section images, high water solubility, high pH resistance and low toxicity in... Agent: Snu R&db Foundation

20110059026 - Pharmaceutical dosage form bearing pregnancy-friendly indicia: A pharmaceutical dosage form comprising at least one active ingredient and destined for administration to pregnant women. The pharmaceutical dosage form bears pregnancy-friendly indicia apt to improve patient compliance with medically recommended dosage regimen resulting in improved product effectiveness. The pregnancy-friendly indicia is also apt to diminish the incidence of... Agent: Duchesnay Inc.

20110059027 - Biocidal aldehyde composition: A novel combination of OPA, a surfactant, and alcohol. The surfactant is preferably a dual chain quaternary ammonium compound consisting of a mixture of alkyl dimethyl-benzylammonium chlorides and alkyl dimethylethylbenzylammonium, that absorbs onto a surface and alters the free energy of that surface. The alcohol is preferably isopropyl alcohol. The... Agent:

20110059028 - Method for membrane electrolysis and the use of the products obtained by it: A metal sulphate is added to the alkali metal chloride solution in membrane electrolysis in order to increase the amount of catholyte solution formed. At the same time, a metal sulphate is added to the anolyte solution in order to improve its stability.... Agent:

20110059029 - Dual component oral care product: A dental composition which, e.g., eliminates or substantially reduces the discomfort and pain associated with dentinal hypersensitivity and exhibits enhanced anticaries and remineralization benefits, which composition contains a first component containing a calcium source, a second component containing an anion source and at least one of the components containing a... Agent: Colgate-palmolive Company

20110059030 - Dental whitening compositions: d

20110059031 - Oral cereal beta glucan compositions: The present invention relates to oral compositions comprising a β (1-3) β (1-4) glucan and one, or more than one compound of interest. In particular, the present invention provides an oral composition comprising an effective amount of a β (1-3) β (1-4) glucan and an effective amount of one, or... Agent: Ceapro Inc.

20110059032 - Hydrocarbon mixtures and use thereof: The invention relates to a hydrocarbon mixture that contains at least two hydrocarbons that are different from each other, the number of carbons thereof differing by more than one, wherein said two hydrocarbons that differ from each other make up at least 60% by weight, preferably at least 70% by... Agent: CognisIPManagement Gmbh

20110059033 - Ultraviolet absorbing composition: (In formula (1), Y11 and Y12 each independently represents monovalent substituent. One of Y11 or Y12 is cyano group, and the other is cyano group, alkylcarbonyl group, arylcarbonyl group, heterocyclic carbonyl group, alkylsulfonyl group, or arylsulfonyl group, carbamoyl group, sulfamoyl group, alkoxycarbonyl group, and aryloxycarbonyl group. V11 and V12 each... Agent: Fujifilm Corporation

20110059034 - Ascorbic acid derivative or salt thereof, production method thereof, and cosmetic: Disclosed is an ascorbic acid derivative or a salt thereof wherein at least one of hydrogen atoms in hydroxy groups at the 2-position and the 3-position of ascorbic acid is substituted by R—O—CH2—CH(OH)—CH2—, R—O—CH2—CH(CH2OH)—, R—CH(CH2OH)—, R—CH(OH)—CH2— (wherein R represents an alkyl group, an alkenyl group or a phenyl group), or... Agent:

20110059035 - Compositions based on polymer/hydrogen peroxide complexes and uses thereof: The invention relates to a cosmetic assembly for improving the appearance of the skin, comprising a first anhydrous composition comprising a polymer-H2O2 complex, said polymer having hydrogen-bond acceptor groups which are capable of forming a noncovalent chemical bond with hydrogen peroxide, and a second composition comprising an activator which promotes... Agent: L"oreal

20110059036 - Nitric oxide-releasing polymers: This invention relates to compositions comprising carbon-based diazeniumdiolates attached to hydrophobic polymers that releases nitric oxide (NO). The carbon-based diazeniumdiolated polymers release NO spontaneously under physiological conditions without subsequence nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated polymers, compositions comprising such polymers, methods of... Agent: Amulet Pharmaceuticals, Inc.

20110059038 - Method of stabilizing a polysiloxane emulsion and compositions containing stabilized emulsions: A method of stabilizing an emulsion containing a polysiloxane and one or more surfactants comprising adding an effective amount of dispersion containing a DADMAC/acrylamide copolymer and one or more sulfate salts into said emulsion is disclosed. An emulsion/cosmetically acceptable emulsion comprising a polysiloxane, at least one surfactant, and a dispersion... Agent:

20110059037 - Polymeric compositions containing ir-emitting/absorbing additives and shaped articles comprised thereof: Polymeric compositions containing additives having properties of emission and/or absorption of radiation in the long infrared region, and articles shaped therefrom are produced, including yarns and textile articles such as fabrics or knits; such additives include organic additives or inorganic fillers which have a capacity for absorption/emission of radiation in... Agent:

20110059039 - Use of peo-pbo block copolymers in ophthalmic compositions: The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone... Agent: Alcon Research, Ltd.

20110059040 - Compositions and methods for inhibiting viral and bacterial activity: Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers.... Agent:

20110059042 - Substituted il-15: The invention provides IL-15 amino acid sequences with amino acid substitutions that reduce or eliminate deamidation of IL-15 and degradation by-products. The invention also provides DNA sequences that encode the substituted amino acid sequences, a pharmaceutical composition comprising the substituted IL-15 amino acid sequence and a pharmaceutically acceptable carrier, and... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service

20110059041 - Vaccine for treatment and prevention of herpes simplex virus infection: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic... Agent:

20110059043 - Chemical compounds: e

20110059044 - Method of treating pulmonary disease with interferons: A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.... Agent: New York University And The Research Foundation Of The State University Of Ny

20110059045 - Pharmaceutical composition for cancer treatment: The invention relates to therapeutic compositions for the treatment of cancer and, more specifically, compositions containing an agonist ligand for receptor 4-1BB and a type-1 interferon, the simultaneous or sequential delivery of which results in a synergic antitumour effect in relation to the individual delivery of any of the components.... Agent: Institut National Dela Sante Et De La Recherche Medicale

20110059046 - Derivatives of gefitinib: This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases.... Agent: Concert Pharmaceuticals Inc.

20110059047 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the... Agent: Intermune, Inc.

20110059057 - Keratinocytes expressing exogenous angiogenic growth factors: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated... Agent: Stratatech Corporation

20110059056 - Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins: The present invention generally relates to the fields of genetic engineering and antibody production. In particular, it relates to the generation of genetically modified vertebrate precursor lymphocytes that have the potential to differentiate into more mature lymphoid lineage cells, and to the use thereof for the production of any heterologous... Agent: 4-antibody Ag

20110059058 - Strain of lactobacillus rhamnosus: The invention relates to a novel strain of Lactobacillus rhamnosus, having antimicrobial and immunomodulatory properties, and to compositions containing said strain.... Agent:

20110059060 - Thuricin cd, an antimicrobial for specifically targeting clostridium difficile: The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective against Clostridium difficile and Listeria monocytogenes amongst other organisms.... Agent:

20110059048 - The fungus fusarium solani strain 'fs-k' and its use in the biological control of plant pathogens and in the enhancement of plant growth and productivity: This invention refers to the pure culture of a wild isolate of the fungal species Fusarium solani (code name: strain ‘Fs-K’) and to its use for the biological control of plant pathogens. The invention includes the mycelium of the strain ‘Fs-K’ and any genetic modification of it, the asexually produced... Agent:

20110059049 - Poxviral oncolytic vectors: A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.... Agent:

20110059052 - Cellular therapeutic agent for incontinence or urine comprising stem cells originated from decidua or adipose: The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or... Agent: Rnl Bio Co., Ltd.

20110059054 - Enhanced dendritic cells for cancer immunotherapy: Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells.... Agent: The Regents Of The University Of Michigan

20110059053 - Method of treating biocells: A method of treating biocells includes the steps of: a. providing biocells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, thereby putting the biocells in a catabolic state during which catabolic metabolic functions predominate over anabolic metabolic... Agent: Battelle Memorial Institute

20110059050 - Methods and compositions relating to stem cell transplantation: The invention relates to methods and compositions for stem cell transplantation. Aspects of the invention relate to administering hematopoietic stem cells and mesemchymal cells to a patient.... Agent:

20110059051 - Molecular control of brown fat differentiation and engergy expenditure: The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of Prdm 16 activity or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of Prdm 16 expression or activity. Further provided are methods for... Agent: Dana-farber Cancer Institute, Inc.

20110059055 - Treating myelin diseases with optimized cell preparations: The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.... Agent: University Of Rochester

20110059059 - Methods for treating ischemic tissue: Compositions and methods for treating ischemic tissue are provided herein.... Agent: Theregen, Inc.

20110059061 - Bioabsorbable surgical composition: Bioabsorbable macromer compositions are provided including a diisocyanate-functional bioabsorbable polymer. In some embodiments, the diisocyanate-functional bioabsorbable polymer can be combined with a functionalized polyol. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.... Agent: Tyco Healthcare Group Lp

20110059062 - Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages: A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by Mycoplasma pneumoniae. In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a... Agent:

20110059063 - Antigen binding proteins that bind par-2: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides human antibodies that bind PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives... Agent: Amgen Inc.

20110059065 - Function and regulation of adamts-1: The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1.... Agent: The Trustees Of The University Of Pennsylvania

20110059067 - Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides: The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.... Agent: Idera Pharmaceuticals, Inc.

20110059066 - Paks as modifiers of the chk pathway and methods of use: Human PAK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of PAK are provided.... Agent: Exelixis, Inc.

20110059064 - Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) w/high selectivity and decrease the in vivo dth-responses in rats: Potassium channels Kv1.3 are known to be implicated in immunological diseases and graft rejections. Disclosed are peptides capable of blocking with high affinity and specificity potassium channels Kv1.3, their pharmaceutical compositions, and methods for their use to block Kv1.3 potassium channels, to treat various immunological conditions and to diagnostic applications.... Agent:

20110059068 - Polypeptides involved in immune response: Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.... Agent: Amgen Canda Inc.

20110059082 - Agent for treating disease: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.... Agent:

20110059083 - Agent for treating disease: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.... Agent:

20110059084 - Agent for treating disease: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.... Agent:

20110059075 - Aglycosylated immunoglobulin mutants: The present invention is based, in part, on our discovery of immunoglobulins (e.g., immunoglobulin G (IgG)) polypeptides (e.g., murine or human IgG, such as human IgG1) that are aglycosylated yet retain the ability to bind to an Fc receptor, such as an activating Fc receptor (e.g., Fcy RIIA and/or FcyRIIIA).... Agent: Massachusetts Institute Of Technology

20110059078 - Anti-ifnar1 antibodies with reduced fc ligand affinity: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.... Agent: Medimmune, LLC

20110059079 - Antibody coformulations: This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0.... Agent: Xoma Technology Ltd.

20110059070 - Combination therapy for tumoral desease treatment: The invention provides a method of treating cancer by administering to a subject in need thereof, the subject being treated with an anti-cancer antibody therapy, a therapeutically effective amount of a delocalized lipophilic cation (DLC) compound such as MKT-077 which is capable of binding mortalin as an adjuvant for the... Agent: Ramot At Tel Aviv University Ltd.

20110059069 - Gapr-1 methods: Methods of treatment, diagnosis and screening related to GAPR-1 are disclosed.... Agent: Biogen Idec Ma Inc

20110059076 - Human serum albumin linkers and conjugates thereof: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates... Agent:

20110059077 - Humanized anti-human alpha 9-integrin antibody: The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a... Agent: Astellas Pharma Inc.

20110059074 - Knowledge-based proliferation signatures and methods of use: The present invention provides methods and compositions for predicting patient responses to cancer treatment using a proliferation gene signature. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for... Agent:

20110059072 - Method for treating cancer using monoclonal antibodies: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies

20110059073 - Method for treating infectious disease using monoclonal antibodies: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies

20110059081 - Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders: The present disclosure provides methods and compositions for treating a disease or disorder in a subject, the method comprising, administering to the subject a therapeutically effective amount of one or more receptor tyrosine kinase inhibitors and a therapeutically effective amount of one or more inhibitors of the dihydrofolate reductase (DHFR)... Agent: Quintiles Transnational Corp.

20110059085 - Staphylococcus aureus-specific antibody preparations: A new antibody-based strategy for treating or preventing Staphylococcus aureus infections utilizes IgM antibodies specific for one or more Staphylococcus aureus capsular antigens. Examples of such antibodies include (i) a polyclonal IgM antibody composition that is isolated from pooled donor plasma and enriched for those IgMs that specifically bind Staphylococcus... Agent: Strox Biopharmaceuticals, LLC

20110059080 - Use of an anti-il6 antibody to decrease hepcidin in cancer patients: A method of reducing serum hepcidin in a patent having a malignancy or lymphoproliferative disorder by administering an IL-6 neutralizing antibody.... Agent:

20110059071 - Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections: The invention relates to the use of monoclonal antibodies which are specific for CD28 and activate the T lymphocytes of several up to all subgroups without the occupation of an antigen receptor of the T lymphocytes and which therefor activate said lymphocytes in an antigen unspecific manner or the invention... Agent:

20110059086 - Espfu nucleic acids and proteins and uses thereof: Disclosed are EspFU (EspF-like polypeptide encoded by a gene of the cryptic prophage CP-933U of enterohemorrhagic E. coli) polypeptides, fragments thereof, nucleic acids that encode EspFU polypeptides, or fragments thereof, and cells including the polypeptides, fragments, and/or nucleic acids. Also disclosed are model systems, kits, and methods for screening that... Agent: University Of Massachusetts

20110059087 - Il-17 and il-23 antagonists and methods of using the same: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.... Agent: Zymogenetics, Inc.

20110059088 - Protein involved in ovarian cancer: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate... Agent: Cell Tech R&d Limited

20110059089 - Protein markers for cardiovascular events: The present invention relates to a method for predicting the risk of a subject developing a cardiovascular event comprising detecting at least one biomarker in (a sample of) the cardiovascular system from said subject, wherein said biomarker comprises at least one protein selected from the group consisting of Tumor Necrosis... Agent:

20110059090 - Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.... Agent: Ablynx N.v.

20110059091 - Inhibitors of oncogenic isoforms and uses thereof: Isoform-binding molecules that specifically bind to one or more isoforms expressed and/or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding molecules can be used to treat, prevent and/or diagnose cancerous conditions and/or disorders. Methods of using the isoform-binding molecules to... Agent:

20110059092 - Antibodies specific of the beta-amyloid peptides and their uses as diagnostic agents or drugs: The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of Aβ8-x peptide, x being comprised from 11 to 42, and recognises neither Aβ1-40 nor Aβ1-42 and which presents a high affinity with respect to Aβ8-x peptide, such as determined by an immunological complex formation... Agent: Sanofi-aventis

20110059094 - Antitumor effects of insulin-responsive dna binding protein-1 (irdbp-1): Methods of inhibiting growth of tumor cells with a nucleic acid encoding IRDBP-1 or the carboxyl segment thereof are disclosed. Also disclosed are methods for treating tumor with an antibody specific against one of the epitopes in the amino segment of IRDBP-1. In addition, methods of identifying a compound that... Agent:

20110059095 - High affinity human antibodies to human protease-activated receptor-2: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders... Agent: Regeneron Pharmaceuticals, Inc.

20110059096 - Targeting of notch3 receptor function for cancer therapy: The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided.... Agent:

20110059093 - Use of an anti-tau ps422 antibody for the treatment of brain diseases: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of... Agent:

20110059097 - Mfap4 as a marker for regulatory cells and anti-cancer cells: The present application provides a novel antibody that is specific for MFAP4. The application also provides methods and uses of MFAP4 as a marker for regulatory cells and/or anti-cancer cells. Further, the application provides methods and uses of MFAP4 binding agents for selection and activation of regulatory cells and/or anti-cancer... Agent: University Health Network

20110059098 - Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof: The invention fully humanized monoclonal antibodies that neutralize Bacillus anthracis. Also provided are methods of treating or preventing a Bacillus anthracis infection. The invention also provides methods of passive vaccination of a subject against Bacillus anthracis.... Agent: Iq Therapeutics Bv

20110059099 - Treatment of idiopathic thrombocytopenic purpura: The present invention pertains to the treatment of idiopathic thrombocytopenic purpura (ITP) employing pharmaceutical compositions containing a VLA-4 antagonist as active ingredient. The VLA-4 antagonists may be in form of chemical compounds or antibodies specifically blocking VLA-4 activity avoiding side-effects.... Agent: Sahltech I G&#xd5 Teborg Ab

20110059100 - C/clp antagonists and methods of use thereof: The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for... Agent: Yale University

20110059101 - Amino acid sequences directed against il-6 and polypetides comprising the same for the treatment of diseases and disorders associated with il-6 mediated signalling: The present invention relates to amino acid sequences that are directed against interleukin-6 (IL-6), as well as to compounds or constructs, and in particular proteins and polypeptides that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino... Agent: Ablynx N.v.

20110059107 - Antikine antibodies that bind to multiple cc chemokines: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.... Agent: Vlst Corporation

20110059104 - Apo-2l receptor agonist and cpt-11 synergism: Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.... Agent: Genentech, Inc.

20110059103 - Future cardiac event biomarkers: The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases.... Agent:

20110059106 - Methods for modulating a population of myeloid-derived suppressor cells and uses thereof: The invention provides for methods of modulating a population of myeloid-derived suppressor cells (MDSCs) in a subject, for treating an autoimmune disease, and also treating cancer in a subject in need thereof. The methods comprise administering to the subject a therapeutically effective amount of an agent that modulates the Tim-3... Agent: Brigham And Women's Hospital, Inc.

20110059108 - Methods of modulating apoptosis by administration of relaxin agonists or antagonists: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist... Agent: Molecular Medicine Research Institute

20110059102 - Therapeutic method targeting midkine: Provided is a therapeutic method targeting midkine for treating mammalian kidney disorders, primary kidney disorders, hypertension that follows secondary kidney disorders such as diabetic nephropathy, and hypertension secondary to chronic kidney disease.... Agent: National University Corporation Nagoya University

20110059105 - Tie complex binding proteins: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.... Agent: Dyax Corp.

20110059112 - Anti-robo4 antibodies and uses therefor: The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.... Agent: Genentech, Inc.

20110059110 - Antibody (11c7) anti nogo-a and its pharmaceutical use: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising... Agent:

20110059113 - Gab2 amplification in melanoma: Provided herein are methods of detecting or inhibiting melanoma growth based on Gab2 protein expression. Gab2 protein was found to be either amplified and/or overexpressed in melanoma. Gab2 protein expression correlated with clinical melanoma progression and higher levels of expression were seen in metastatic melanomas compared to primary melanoma and... Agent: The Trustees Of Columbia University In The City Of New York

20110059111 - Mammalian receptors as targets for antibody and active vaccination therapy against mold infections: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

20110059109 - Methods for inducing or enhancing an immune response by administering gitr-binding antibodies: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression... Agent:

20110059114 - Compositions and methods for the treatment of radioresistant glioma stem cells: Compositions and uses of gamma secretase inhibitors (GSIs) for the treatment and inhibition of gliomas in subjects in need thereof are provided. Methods for administering gamma secretase inhibitors in association with radiation for the treatment of radiation resistant gliomas are described. Compositions for the inhibition of Notch signaling and activity... Agent: Duke University

20110059115 - Antibody composition exhibiting cellular cytotoxicty due to glycosylation: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for... Agent: Kyowa Hakko Kirin Co., Ltd.

20110059118 - Inhibitors of jak: e

20110059116 - Laser-based vaccine adjuvants: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine... Agent: Ooo "npt Mbp Gormezis"

20110059117 - Liquid compositions capable of foaming and including active agents, and methods for making or developing same: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the... Agent:

20110059119 - Immunogen against campylobacter infection: The invention relates to the use of Campylobacter jejuni gene product jlpA and immunogenic fragments of jlpA as a component of a pharmaceutical formulation capable of eliciting an anti-Campylobacter jejuni immune response. The invention also relates to a method of inducing an anti-Campylobacter immune response by the administration of C.... Agent:

20110059120 - Glucan-based vaccines: Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterised in that, when administered to a mammalian recipient, the composition... Agent:

20110059121 - Compositions and methods for the prevention and treatment of autoimmune conditions: The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used... Agent: Uti Limited Partnership

20110059123 - Inhibition of the survival of colorectal cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of colorectal cancer cells and be used as a pharmaceutical composition to inhibit the colorectal... Agent: Golden Biotechnology Corporation

20110059122 - Inhibition of the survival of oral cavity cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of oral cavity cancer cells and be used as a pharmaceutical composition to inhibit the... Agent: Golden Biotechnology Corporation

20110059124 - The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion: This invention discloses a kind of quality control method and application of Ganoderma lucidium spore oil fat emulsion. Which includes Ganoderma lucidium spore oil 2˜25%, emulsifier 0.5˜10%, isosmotic agent 0.2˜5%, the remaining content is water and the final pH of Fat emulsion is adjusted to 6˜9. The quality control method... Agent: Guangzhou Hanfang Natural Medicine Research & Development Co.ltd

20110059125 - Zwitterionic immunomodulators for the treatment of asthma and allergy: Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.... Agent: The Brigham And Women's Hospital, Inc.

20110059126 - Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity: The present invention provides methods of reducing the vircidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity... Agent: Boehringer Ingelheim Vetmedica, Inc.

20110059127 - Use of mutant hiv-1 protease or siv protease as an adjuvant: The present invention relates to a mutant HIV-1 (Human immunodeficiency virus-1) protease capable of effectively enhancing cell-mediated immune responses to DNA vaccination, and use of a nucleic acid encoding the same as a vaccine adjuvant. The mutant HIV-1 protease according to the present invention has inactivated or attenuated proteolytic activity,... Agent: Postech Foundation

20110059128 - Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird): A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable... Agent: The Royal Veterinary College

20110059129 - Avian influenza virus vaccine and a method for preparing: The present invention relates to an avian influenza vaccine of plant origin, prepared by transforming a plant with a surface protein of avian influenza virus, hemagglutinin (HA) or neuraminidase (NA), and a method for preparing the same. Further, the present invention relates to an oral vaccine for preventing avian influenza... Agent: Sungkyunkwan University Foundation For Corporate Collaboration

20110059130 - Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and subunit vaccine compositions. In... Agent: Fraunhofer Usa, Inc.

20110059131 - Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to... Agent: The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services

20110059132 - Composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases: The present invention relates to a composition, comprising: i) an HBcAg1-x, wherein x is a whole number from the range from 100 to 160, a fragment of this antigen, a variant of this antigen or of the fragment of this antigen or at least two thereof, ii) an adjuvant comprising... Agent:

20110059133 - Ex vivo method for producing a preparation containing cd4+ t cells specific for ebv structural antigens: The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.... Agent: Helmholtz Zentrum Munchen Deutsches Krebsfor Schungszentrum Fur Gesundheit Und Unwelt (gmbh)

20110059134 - Prevention of recurrent viral disease: The present invention discloses compositions and methods for ameliorating or reducing recurrent viral disease, which compositions and methods result in an increase in virus specific immunoglobulin subclasses reflective of a preferential Th1 response.... Agent:

20110059135 - Capsid-incorporated antigen for novel adenovirus vaccine: This invention pertains to tropism-modified adenoviral vectors optimized for antigen delivery that induced both humoral and cellular immune responses, as well as a method of constructing and using such vectors. The vectors of the present invention may incorporate an epitope or an antigen into a capsid protein. Methods for treating... Agent:

20110059136 - Methods and compositions for treating inflammatory bowel disease: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific... Agent:

20110059137 - Chemokine gene-modified cells for cancer immunotherapy: Described herein are methods of cancer immunotherapy, particularly compositions comprising genetically-modified cells that express macrophage colony stimulating factor (GM-CSF), CD40 ligand (CD40L), and chemokine C—C motif ligand 21 (CCL21), wherein the population of cells comprises bystander cells and target cancer cells, and methods of making these compositions and treating cancer... Agent: University Of South Florida

20110059138 - Compositions and methods for enhancing immune system of felines: Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed.... Agent: Hill's Pet Nutrition, Inc.

20110059142 - Encapsulation of biologically active agents: The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment.... Agent:

20110059140 - Extruded rod-shaped devices for controlled release of biological substances to humans and animals: The present invention relates to an extruded rod-shaped device which comprises at least one biological substance and a lipoid composition that comprises a high melting lipid or lipoid component and a low melting lipid or lipoid component. The extruded rod-shaped device according to the present invention is obtainable by extrusion... Agent:

20110059139 - Method for loading a molecule into a porous substrate: e

20110059141 - Percutaneous absorption preparations of antidementia drugs: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a... Agent:

20110059144 - Encapsulated hydrophobic actives via interfacial polymerization: The present invention provides personal care compositions, as well as methods for protecting low viscosity hydrophobic liquid actives.... Agent:

20110059143 - Non-textile polymer compositions and methods: Included are polymer compositions such as polyurethaneureas, polyamides and polyesters. The compositions may be in a variety of forms such as dispersions, powders, fibers, and beads. The compositions are useful in the preparation of many products including health and beauty products such as cosmetics, paint, household products such as fabric... Agent: Invista North Americ S.a.r.l.

20110059145 - Topical composition for external use and process for producing the same: A topical composition for external use comprising: a ceramide analogue-containing particle having a particle diameter of 0.001 μm to 0.2 μm; and a water-soluble polymer. It is preferable that, further, an oil component different from the ceramide analogue is contained in an amount of 20 parts by mass or less... Agent: Fujifilm Corporation

20110059146 - Antimicrobial materials: The disclosure provides methods and materials suitable for preparing coating layers on substrates. The coatings comprise quaternary amine groups and therefore impart anti-bacterial properties to the substrate. In one embodiment, for example, there is provided a quaternary amine-containing polymeric coating comprising propylene and ethylene repeat units.... Agent:

20110059147 - Long term drug delivery devices with polyurethane based polymers and their manufacture: e

20110059152 - Augmentation of organ function: The present invention provides methods and compositions for augmenting organ functions using small-scale matrix implants generated by seeding tissue-specific or undifferentiated cells onto a matrix materials (e.g., a wafer, sponge, or hydrogel). The seeded matrix composition can then be implanted and will develop into an organ-supplementing structure in vivo. Continued... Agent: Children's Medical Center Corporation

20110059150 - Coating method: A method of coating a material onto projections provided on a patch. The method includes applying a coating solution containing the material to at least the projections and drying the coating solution to at least the projections using a gas flow.... Agent: The University Of Queensland

20110059148 - Flexible drug delivery chip, its fabrication method and uses thereof: Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring... Agent: National Chiao Tung University

20110059151 - Porous biomaterial on hydropatite: The present invention provides a synthetic non-resorbable silicon-containing calcium phosphate biomaterial having a microporosity of 23% by volume or greater, wherein the surface free energy of the biomaterial is 19 mJ/m... Agent: Apatech Ltd

20110059149 - Process for depositing calcium phosphate therapeutic coatings with different release rates and a prosthesis coated via the process: A method of coating a substrate including loading a calcium phosphate substance at a first crystallinity with a therapeutic agent; depositing the loaded calcium phosphate substance at the first crystallinity onto a least a portion of the substance; loading a calcium phosphate substance at a second, lower, crystallinity with a... Agent:

20110059153 - Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome: Methods for treating carpal tunnel syndrome and tarsal tunnel syndrome in a subject involve providing an effective amount of an anti-cytokine agent at or near inflammation in the carpal or tarsal tunnel. Anti-cytokine agents, such as, TNF-a inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors,... Agent: Warsaw Orthopedic, Inc.

20110059154 - Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same: Topical cream, ointment, lotion, gel, foam formulations and slow release formulations or devices are provided including certain CCR5 antagonists as prophylactics for the prevention, retardation or inhibition of transmission of Human Immunodeficiency Virus (HIV) infection from one human to another.... Agent:

20110059155 - Water resistant patch preparation: The present invention provides a water resistant patch preparation having a central part and a peripheral part, which preparation is comprised of a support and an adhesive layer comprising a drug, which is formed on one surface of the support, wherein at least a part of a lateral end of... Agent: Nitto Denko Corporation

20110059157 - Anionic lipids and lipid nano-structures and methods of producing and using same: Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same.... Agent:

20110059158 - Charged phospholipid compositions and methods for their use: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of... Agent: Cerenis Therapeutics Holding Sa

20110059163 - Lyophilised antigen composition: The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making... Agent:

20110059160 - Methods and compositions for targeted gene modification: Disclosed herein are methods and compositions for gene targeting utilizing fusion molecules comprising a recombinase domain and a sequence-specific DNA-binding domain.... Agent:

20110059159 - Nanoscale bound bilayers, methods of use and production: Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of... Agent: The Rockefeller University

20110059156 - Nanostructures suitable for sequestering cholesterol and other molecules: Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that... Agent: Northwestern University

20110059162 - Tannin-chitosan composites: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable... Agent:

20110059161 - Targeted delivery using tissue-specific peptidomimetic ligands: Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A′ and one or more hydrophobic anchors covalently linked to the scaffold. The A and A′ compounds linked to the scaffold comprise monovalent... Agent: Gradalis, Inc.

20110059164 - Encapsulation of oxidatively unstable compounds: An encapsulated material containing an oxidation-sensitive core is covered by at least a dried synthetic organelle layer and optional additional ingredients in the organelle layer or additional layers. By using microencapsulation to mimic or otherwise adapt the storage concepts used by seeds to protect triacylglycerol cores, oxidatively unstable materials may... Agent: Aveka, Inc.

20110059165 - Seamless alginate capsules: The present invention is directed to a dried seamless capsule comprising an alginate shell membrane encapsulating fill material, wherein: (i) said alginate shell membrane comprises a polyvalent metal ion alginate having: (a) an average M content of from 50%-62% by weight based on the weight of the M and G... Agent: Fmc Corporation

20110059166 - High strength seamless alginate capsules: The invention is directed to a seamless alginate capsule having a film encapsulating a fill material, in which the film comprises alginate, noncrystallizing plasticizer, and glycerol and in which a ratio by weight of noncrystallizing plasticizer to glycerol in the film is between about 1:1 and about 8:1. The invention... Agent: Fmc Corporation

20110059167 - Encapsulation of biologically active agents: The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment.... Agent: Glaxo Group Limited

20110059168 - Method for correcting intestinal glutamine synthetase deficiency: The method includes steps of providing non-pathogenic glutamine-synthetase-producing bacteria, introducing the provided non-pathogenic glutamine-synthetase-producing bacteria into intestines, releasing the introduced non-pathogenic glutamine-synthetase-producing bacteria in the intestines in a predetermined time period, and normalizing serum level of free glutamate and halting continual flooding of free glutamate into the brain.... Agent:

20110059169 - Method and composition for administering an nmda receptor antagonist to a subject: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... Agent: Adamas Pharmaceuticals, Inc.

20110059170 - Methods for administering weight loss medications: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of... Agent: Orexigen Therapeutics, Inc.

20110059171 - Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles: The invention relates to a solid oral pharmaceutical composition combining ketorolac and B-complex consisting of inter alia thiamin, pyridoxine and cyanocobalamin (vitamins B1, B6 and B12 respectively) and/or the pharmaceutically acceptable salts thereof, as well as pharmaceutically acceptable excipients and/or vehicles. The invention also relates to the method for producing... Agent: Laboratorios Senosiain S.a. De C.v.

20110059173 - Compositions and methods for promoting wound healing and tissue regeneration: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.... Agent: Musc Foundation For Research Development

20110059174 - Pkcdelta regulates neuroinflammatory events: This invention relates to methods and pharmaceutical compositions for regulating the levels of proinflammatory substances released from activated microglia using a protein kinase C delta (PKCd) inhibitor. In particular, it relates to decreasing the levels of proinflammatory substances produced within the microglial cells or released from activated microglical cells or... Agent: Iowa State University Research Foundation, Inc.

20110059172 - Therapeutic compositions: Therapeutic compositions containing therapeutic agents and poly(beta-amino esters) or polymers thereof are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles and microparticles containing polymer/therapeutic agent complexes are also described.... Agent:

20110059175 - Enhancing solubility and dissolution rate of poorly soluble drugs: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution... Agent: K.u.leuven Research And Development

20110059176 - Material for preventing tissue adhesion and material for preventing joint contracture: e

20110059177 - Cardioplegia solution for cardiac surgery: The invention relates to improved cardioplegia solutions. The invention provides cardioplegia solutions and compositions that produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The cardioplegia solutions and compositions are used for arresting, protecting and/or preserving organs, in particular the heart during open-heart surgery, transplanting, cardiovascular diagnosis or... Agent:

20110059178 - Tissue engineered meniscus repair composition: A meniscus repair composition for application to a meniscus defect site to promote growth of new tissue at the meniscus defect site is provided. The composition comprises: from about 10 to about 50 percent by weight of allograft meniscus particles having an average particle size of from about 10 μm... Agent: Musculoskeletal Transplant Foundation Inc.

20110059179 - controlled delivery system that provides malodor management over a prolonged period of time: The present invention relates to an improved controlled delivery system that can be incorporated into personal and household care products, such as deodorants, body wash, hair products, air refresher, fabric refresher, and other personal and household products, for the counteraction and management of malodor. The controlled delivery system of the... Agent:

20110059180 - Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorisation of therapeutic agents, especially anti-tumoral agents.... Agent:

20110059181 - Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles: The present invention provides preparation methods of protein nanoparticles for in vivo delivery of pharmacologically active agents, wherein said methods are to encase pharmaceutically active agents into proteins or peptides to form nanoparticles by unfolding the protein, and subsequently refolding or assembling the protein to produce a pharmacologically active agent... Agent: Nanopax Pharma, LLC

20110059182 - Spraying device and related method for cell aggregates and cell aggregate suspension thereof: A sprayer device and related method that delivers multicellular aggregates in suspension. A purpose of the sprayer embodiment may be to deliver cells into chronic wound beds, and additional purposes of the sprayer include additional application in other cell delivery environments, such as during open-heart surgery or other surgeries where... Agent: University Of Virginia Patent Foundation

20110059183 - Water-insoluble medicine: A method of producing water-insoluble anti-cancer drug in the form of particulates, the method including preparing a water-insoluble anti-cancer drug having at least one multiple bond in the structure, and irradiating said water-insoluble anti-cancer drug with a laser beam having a wavelength of a low absorption portion in the vicinity... Agent: Ebara Corporation

20110059184 - Medicament for treating parkinson's disease: The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, bee's venom is used in an amount of between 33 and 330 micrograms inclusive, for the manufacture... Agent: Assistance Publique - Hopitaux De Paris

20110059185 - Method for in-process decontamination in food preparation and processing and for reducing microbial content in cosmetics, pharmaceuticals, daily-care products and animal and plant food and for treatment of surfaces: The present invention relates to a novel method for in-process decontamination in food preparation and processing using an aqueous, health-wise non-hazardous cleaning medium. The invention further relates to a method for treating surfaces and for reducing the microbial content with an aqueous, health-wise non-hazardous medium which is more effective than... Agent: Aquagroup Ag

20110059186 - Cancer stem cell-targeted and drug resistant cancer therapy: The present invention provides methods for preventing, treating, and/or managing cancer, the method comprising administering to a subject in need thereof therapeutically effective amount of sodium meta arsenite that reduces or eliminates drug resistant cancer stem cell populations as well as drug resistant mature cancer cells.... Agent: Kominox Usa, Inc.

20110059187 - Peptide dicer substrate agents and methods for their specific inhibition of gene expression: This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA)-peptide conjugates.... Agent: Dicerna Pharmaceuticals, Inc.

20110059188 - Compositions for reducing dental erosion: The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for the reduction of dental erosion caused by exposure to acidic compositions having a pH in the range 2.0 to 5.0.... Agent:

20110059189 - Method and composition for treating cancer, effecting apoptosis and treating retroviral infections: A modified sodium silicate composition, and methods of treating cancer and viral infections utilizing the modified sodium silicate composition (Na8.2Si4.4H9.7O17.6). Na8.2Si4.4H9.7O17.6 can be administered to increase the nitric oxide concentration in the body, effect apoptosis, increase NO formation by neutrophils. Inhibit cell mutations, and inhibit oxidative stress.... Agent: Cisne Enterprises Inc.

20110059191 - Bcl-2 protein expressing agent, apoptosis inhibiting agent and agent for preventing ultraviolet dna damage of epidermal cell: An apoptosis inhibiting agent for an epidermal cell, containing a water and ethanol-soluble glycyrrhiza extract as an active ingredient. The apoptosis inhibiting agent has an anti-apoptotic factor due to expression of BLC-2 protein, and has the property of preventing a DNA damage due to ultraviolet-rays. The agent alleviates the DNA... Agent: Nishihara Co., Ltd.

20110059190 - Cistus extract containing enriched secondary plant ingredients: The invention relates to a method for producing an extract containing at least 40% (m/m) of polyphenols from Cistus creticus L., said method comprising the following steps: plant parts are extracted from Cistus creticus L. using an extraction agent selected from the group comprising water, alcohols and mixtures thereof; the... Agent: Finzelberg Gmbh & Co. Kg

20110059192 - Methods and compositions for modulating hair growth or regrowth: The present invention relates to compositions and methods for modulating hair growth or regrowth. The compositions of the present invention include extracts of one or more of the following: Boswellia serrata, Undaria pinnatifida, green tea (e.g., Camellia sinensis), shiso, Pureraria mirifica, luteolin (e.g. Perilla ocymoides leaf extract), astilbin, vitamin E,... Agent:

20110059193 - Method for obtaining an extract of cranberry marc that can be used in particular in the prevention and treatment of conditions such as caries, gingivitis or sore throats: A a method for obtaining an extract prepared from cranberry (genus Vaccinium macrocarpon and/or Vaccinium oxycoccus) marc, with a view to obtaining a product that, provided in various galenical forms or other, has, owing to the high concentration of proanthocyanidins, in particular type A proanthocyanidins, therein, many therapeutic qualities and... Agent: Tournay Biotechnologies, Sas

20110059194 - Echinacea formulation: The present invention relates to an Echinacea formulation which includes an alkylamide fraction comprising a 2-ene alkylamide fraction and a 2,4-diene alkylamide fraction and the weight ratio of the 2-ene alkylamide fraction to the 2,4-diene alkylamide fraction is between about 1:15 to about 2:1.... Agent: Mediherb Holdings Ltd.

20110059195 - Swinglea glutinosa leaves derived material in combination with pyrethroids for control of acari: The invention of the present application provides a natural material derived from Swinglea glutinosa leaves that in combination with low doses of pyrethroids, maintains the effect of high doses of pyrethroids over mites. The material derived from Swinglea glutinosa leaves, in a preparation with pyrethroids, results in a mix material... Agent:

20110052489 - Anti-cd19 antibodies: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In... Agent:

20110052488 - Methods for treating, diagnosing, and monitoring rheumatoid arthritis: Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.... Agent:

20110052490 - Endoscopic mucosal resectioning using purified inverse thermosensitive polymers: One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal... Agent:

20110052491 - Gastrin releasing peptide compounds: New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging... Agent:

20110052492 - Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy: This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be... Agent:

20110052498 - Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders: A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an... Agent:

20110052494 - H-antigen binding polypeptides and methods of use: Polypeptides having high specific binding for H-antigen, particularly Lewis y and Lewis b antigens are described. The polypeptides are useful in making conjugates with diagnostic reporter molecules or therapeutic agents such as anticancer agents for binding to epithelial derived tumors or cancer cells which overexpress such antigens.... Agent:

20110052496 - Hollow nanoparticles and uses thereof: Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains.... Agent:

20110052497 - Minimally invasive systems and methods for in vivo testing of materials: Implantable material testing devices and method of testing materials in an animals are provided. In one embodiment, a method of testing a material in an animal includes associating the material with a retention frame to form a testing device. The retention frame movable between a first shape suited for insertion... Agent:

20110052495 - Use of fullerenes in photoacoustic imaging: Fullerenes, when irradiated with electromagnetic radiation, generate acoustic waves. A photoacoustic tomography method using a material comprising fullerenes is disclosed that includes irradiating the material with a radiation beam such as a laser. The resultant photoacoustic effect produced by the material is detected by at least one detector. A photoacoustic... Agent:

20110052493 - Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases... Agent:

20110052499 - Baboon homolog of human cd147: Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed.... Agent:

20110052502 - Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof: Methods and compositions for the diagnosis, prognosis and/or treatment of leukemia associated diseases are disclosed.... Agent:

20110052501 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention... Agent:

20110052500 - Taj in neuronal function: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.... Agent:

20110052503 - Biodegradable contrast agents: The present invention provides a radio-opaque composition comprising a cleavable, preferably enzymatically-cleavable, derivative of a physiologically tolerable organoiodine compound and a non-acrylic polymer wherein said derivative is incorporated in said non-acrylic polymer.... Agent:

20110052504 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CO—CH3)XN(CO—CH3)—R and salts or optical active isomers thereof,... Agent:

20110052505 - Post-biopsy cavity treatment implants and methods: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second... Agent:

20110052506 - Stable aerosol topical foams comprising a hypochlorite salt: Described herein are compositions useful in the treatment of atopic dermatitis and other skin conditions, which compositions exhibit enhanced stability. The compositions contain a hypochlorite salt, useful for its antimicrobial properties, and are non-irritating when applied to the skin. The compositions also provide enhanced moisturizing properties. The compositions can be... Agent:

20110052509 - Compositions comprising basic amino acid and soluble carbonate salt: This invention relates to compositions comprising a basic amino acid free or salt form and a soluble carbonate or bicarbonate salt.... Agent:

20110052507 - Oral care compositions comprising casein, ovalbumin, whey or soy protein: The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear caused by subsequent exposure to acid.... Agent:

20110052508 - Peptide-based oral care surface reagents for personal care: Peptides have been identified that bind to oral surfaces such as teeth and gums. Peptide based oral care reagents have been created by couple such peptides to oral care benefit agents such as whiteners.... Agent:

20110052510 - Tooth movement activating compound: The invention relates to the development of a food or edible product of oleic origin, which acts as a dental lubricant and is intended to reduce friction between orthodontic wires and brackets, thereby providing low, more continuous physiological forces and, consequently, a significant reduction in orthodontic treatment times. The invention... Agent:

20110052515 - Avermectin/benzoyl peroxide compositions for treating affliction of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea.... Agent:

20110052513 - Cationic surfactant compounds, use thereof as conditioner, cosmetic treatment method, and cosmetic or pharmaceutical compositions comprising same: The present patent application relates to novel surface-active cationic compounds, to their use, in particular as hair conditioning agent, to a cosmetic treatment method, in particular for the hair, employing the said compounds, and to the cosmetic or pharmaceutical compositions, in particular hair compositions, comprising the said surfactants.... Agent:

20110052512 - Composition containing a hydroxylated diphenylmethane derivative: The invention relates to a composition in the form of an oil-in-water emulsion containing an ester of fatty acid and of polyethylene glycol, an additional surfactant chosen from esters of C16-C22 fatty acid and of sorbitan and esters of C16-C22 fatty acid and of glycerol, a polycondensate of ethylene oxide... Agent:

20110052511 - Novel use of organic compounds: The present invention is directed to the use of a compound selected from the group consisting of β-carotene, lutein, lycopene and β-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including... Agent:

20110052514 - Use of natural active substances in cosmetic or therapeutic compositions: The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment.... Agent:

20110052516 - Sunscreens: The present invention relates to the use of phosphate ester surfactants for increasing the sun protection factors (SPF's) of topical compositions which comprise at least on UV-filter substance. Furthermore, the invention relates to topical compositions comprising a phosphate ester surfactant and at least 4 wt-% of butyl methoxydibenzoylmethane in combination... Agent:

20110052518 - Bleaching/highlighting composition containing calcium salts: The present invention relates to bleaching composition for keratin fibres, especially human hair, comprising at least one compound with bleaching and/or highlighting effect and a calcium salt. Further object of the present invention is the use of at least one calcium salt in a bleaching and/or highlighting composition for keratin... Agent:

20110052517 - Cosmetic uses of modified stressed yeast extracts and related compositions: Cosmetic compositions comprising a metal-complexed peptide fraction of stressed yeast extracts and/or a calcium influx inhibitor are disclosed, as well as methods of using such compositions to impart exfoliating, anti-aging, anti-lipid, anti-inflammatory, and/or lightening benefits to the skin; and/or lightening benefits to the hair. These compositions are believed to have... Agent:

20110052519 - Peptide derivatives useful in the treatment, care or cleansing of the skin, mucosae, scalp or nails: their stereoisomers, mixtures thereof, and their cosmetically or pharmaceutically acceptable salts, a method for obtaining them, cosmetic or pharmaceutical compositions containing them and their use for the treatment, care and/or cleansing of those conditions, disorders and/or pathologies of the skin, mucosae, scalp and/or nails resulting from microorganism proliferation or being... Agent:

20110052521 - Oil-in-water organopolysiloxane emulsion composition, cosmetic ingredient comprising this composition, and method of producing a hair cosmetic using this composition: To provide a highly storage-stable nonionic oil-in-water organosiloxane emulsion composition that substantially does not contain ionic surfactant and that on a long-term basis does not undergo separation of the emulsion composition. An oil-in-water organosiloxane emulsion composition that characteristically comprises (A) 100 weight parts of organosiloxane, (B) 0.5 to 35 weight... Agent:

20110052520 - Use of a composition and process involving the use of a non-hydroxide base and a protein denaturant with heat for relaxing or straightening hair: A process for straightening or relaxing hair involving the steps of: (a) providing a hair straightening/relaxing composition containing: (i) from about 0.1 to about 50% by weight of at least one non-hydroxide base; (ii) from about greater than 0% to about 50% of at least one protein denaturant; and (iii)... Agent:

20110052522 - Cosmetics comprising cistus plant extracts: The present invention relates to the use of an extract from cistus, prepared by a novel process, as care active ingredient for the care of human or animal body parts, to care formulations and to the use of the care formulations.... Agent:

20110052523 - Organopolysiloxane compound and amidoamine compound, and cosmetic preparation: wherein R2 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an alkali metal, A independently represents an alkylene group, B represents —NR3—, sulfur or oxygen atom, n is 0 or 2, n1 is 0 or 1, and n2 is 0 or 1 provided that... Agent:

20110052524 - vertebroplasty method using an addition curable polysiloxane system: The invention relates generally to treatments of disordered bony structures, in particular to vertebroplasty compositions and methods and, more specifically, to treating vertebral bodies in living creatures, in particular, human beings and also compositions suitable for use in such methods and preparation and use of such compositions. According to the... Agent:

20110052525 - Breaking immunological tolerance with a genetically encoded unnatural amino acid: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against... Agent:

20110052527 - Imidazopyridinyl thiazolyl histone deacetylase inhibitors: A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent:

20110052526 - Method and composition for neochondrogenesis: A method of neochondrogenesis, where following microfracture surgery or subchondral drilling, includes administering injections of an effective amount of a composition to the damaged, affected connective tissue, for example knee joint cartilage. The composition includes a mixture of hyaluronic acid combined with harvested stem cells, for example autologous peripheral blood-derived... Agent:

20110052530 - Adoptive cell therapy with young t cells: The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein... Agent:

20110052533 - Compositions and methods for cartilage repair: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.... Agent:

20110052531 - Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat peripheral neuropathies, including toxin-induced peripheral neuropathy and diabetic as well as manufacture of medicaments including tablets, capsules, and other orally active compositions containing cG-2-allylP, as well as injectable solutions that are useful for treatment of... Agent:

20110052529 - Methods and compositions for expanding t regulatory cells: The present invention provides methods and compositions for expanding Treg cells ex vivo or in vivo using one or more conjugates comprising a costimulatory moiety that stimulates at least one of three signals involved in Treg cell development and/or using dendritic cells pulsed with antigens and modified to display TGF-β,... Agent:

20110052528 - Neuroprotective macrocyclic compounds and methods for their use: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.... Agent:

20110052532 - Pharmaceutical composition comprising a cytokine: The present invention relates to a pharmaceutical composition comprising, (i) a cytokine and, (ii) a compound of the general formula (Ih) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof. Exemplary cytokines are selected from the following group of cytokine... Agent:

20110052534 - Imidazopyridazine compounds for treating viral infections: Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses:... Agent:

20110052535 - Compositions for treating an inflammatory autoimmune condition: The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition.... Agent:

20110052536 - Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection: Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of treating HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in... Agent:

20110052537 - Nitro-based explosive remediation: Embodiments of techniques for remediating soil contaminated with compounds, particularly nitro-based explosives, are disclosed. Plants capable of taking up the compounds are grown within contaminated soil for a period of time. The plants are exposed to anaerobic microbes in the rumen of a ruminant animal. The ruminal anaerobic microbes degrade... Agent:

20110052538 - Probiotic/non-probiotic combinations: This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH,... Agent:

20110052553 - Strain of lactobacillus plantarum lp28 and its use in treating hypersensitivity reactions: A new strain of Lactobacillus plantarum LP28, which has deposited at Bioresource Collection and Research Center of Taiwan with a deposited number of BCRC No. 910435, also at China General Microbiological Culture Collection Center (CGMCC), has a deposit number of CGMCC No. 3346. The Lactobacillus plantarum LP28 or its metabolic... Agent:

20110052555 - Pesticide composition comprising a tetrazolyloxime derivative and a fungicide or an insecticide active substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative... Agent:

20110052540 - Non-aggregating virus formulation: The present invention is a composition comprising a virus, a polyol and a zwitteronic compound. The present invention is also an assay for viral aggregation, which comprises analysing the size of the viral particles in a sample, wherein the particles are in admixture with a polyol, and determining from the... Agent:

20110052541 - Novel bacteriophage and antibacterial composition comprising the same: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for... Agent:

20110052542 - Novel bacteriophage and antibacterial composition comprising the same: Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage... Agent:

20110052543 - Novel bacteriophage and antibacterial composition comprising the same: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for... Agent:

20110052544 - Novel bacteriophage and antibacterial composition comprising the same: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for... Agent:

20110052539 - Oncolytic rhabdovirus: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.... Agent:

20110052551 - Cardiac myocyte morphogenic compositions and methods of use therefor: Disclosed are methods for inducing cardiomyogenic differentiation in cells that are competent for differentiation along the cardiomyogenic lineage such as certain unfractionated bone marrow mononuclear cells (BMMNCs). In some embodiments, the methods include contacting a plurality of unfractionated, density gradient-separated BMMNCs with a cardiomyocyte differentiation-inducing amount of a Wnt11 gene... Agent:

20110052549 - Cell culture device to differentiate stem cells in a specific orientation: Methods and compositions for aligning cell growth is provided by this invention by contacting at least one isolated cell with a device, wherein the device comprises a plurality of continuously orientating substantially parallel structures on the surface of the device, and culturing the cell under conditions that favor division of... Agent:

20110052548 - Cell culture media to differentiate embryonic stem cells into neuronal lineages: This invention provides compositions for differentiating an isolated embryonic stem cell or an isolated embryoid body into neuronal progenitor cells and methods for using same.... Agent:

20110052552 - Compositions to effect neuronal growth: Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed... Agent:

20110052546 - Inhibition of ship to enhance stem cell harvest and transplantation: The instant invention teaches the inhibition of SHIP expression, or function for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation... Agent:

20110052547 - Rapamycin-resistant t cells and therapeutic uses thereof: Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also... Agent:

20110052545 - Regeneration system, its production and use: The present invention relates to a tissue-maintaining colony-forming unit (TM-CFU), a method of preparing the same, a pharmaceutical composition comprising the TM-CFU, the use of the TM-CFU for the manufacture of a pharmaceutical composition, and a method of determining the effect of at least one stimulus on the TM-CFU or... Agent:

20110052550 - Therapeutic uses of allogeneic myeloid progenitor cells: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed... Agent:

20110052554 - Methods for off-the- shelf tumor immunotherapy using allogeneic t-cell precursors: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by... Agent:

20110052556 - Pharmaceutical composition comprising racetam and carnitine and process for its preparation: The present invention refers to a pharmaceutical composition comprising racetam and carnitine. Said pharmaceutical composition may further comprise coenzyme Q10 and/or agent associated with mitochondrial and/or metabolic disturbance, such as hypocholesterolemic agent of the statins group, a hypoglycemic agent, or an antiepileptic agent. The invention also includes a method of... Agent:

20110052557 - Phytocomposition having antimicrobial activity: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material.... Agent:

20110052558 - Materials and methods for prevention and treatment of rna viral diseases: The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one... Agent:

20110052559 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.... Agent:

20110052560 - Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases: The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment the present invention relates to methods for the prophylaxis of mammals, and... Agent:

20110052562 - Benzimidazoles and analogs as rho kinase inhibitors: Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R1, R2 and Ar1 are as defined herein, and any tautomer, salt, stereoisomer, hydrate, solvent, or prodrug thereof, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.... Agent:

20110052561 - Osteolysis treatment: Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist... Agent:

20110052566 - Cognitive function: Inhibition of eIF-2α phosphorylation can be used to improve cognitive function and/or to treat dementia, including Alzheimer's Disease. In particular, this can be achieved by inhibiting the kinase activity of PKR in a non-toxic manner.... Agent:

20110052564 - Enhancement of immunogenicity of antigens: The invention provides means and methods for producing and/or selecting immunogenic compositions, comprising providing said composition with at least one crossbeta structure and testing at least one immunogenic property.... Agent:

20110052563 - Gonadal function improving agents: Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility,... Agent:

20110052567 - Methods compositions, uses, and kits useful for vitamin d deficiency and related disorders: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders; related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin... Agent:

20110052565 - Non-aggregating human vh domains: The present invention relates to non-aggregating VH domains or libraries thereof. The VH domains comprise at least one disulfide linkage-forming cysteine in at least one complementarity-determining region (CDR) and an acidic isoelectric point (pI). A method of increasing the power or efficiency of selection of non-aggregating VH domains comprises panning... Agent:

20110052568 - Tablet comprising natural allicin and method for producing the same: A tablet including 1,000 weight parts of 21-90% natural allicin powder, 10-30 weight parts of 50-95% sesamin, 10-30 weight parts of 50-95% IgY or IgG, and a release agent. The allicin content of the tablet is 200-800 mg/g. The allicin tablet has high allicin content and capability of anti-bacteria and... Agent:

20110052569 - Molecules and methods for treatment of diabetes: Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (GAD65) that is bound by antibody b96 11, and anti-idiotypic antibodies that are capable of competing with GAD65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a... Agent:

20110052573 - 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis: The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided... Agent:

20110052575 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent:

20110052577 - Antibodies: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.... Agent:

20110052578 - Compounds and compositions as protein kinase inhibitors: e

20110052582 - Humanized anti-cdcp1 antibodies: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Agent:

20110052579 - Ligands of the natural killer (nk) cell surface marker cd27 and therapeutic uses thereof,: The present invention relates to the modulation of Natural Killer (NK) cells in vitro or in vivo through the use of activating or inhibiting ligands of CD27, such as antibodies, for a regulation of the immune response against several different diseases, such as viral infections, cancer, bacterial infections, sepsis as... Agent:

20110052571 - Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease... Agent:

20110052584 - Method of enhancement of cytotoxicity in antibody mediated immune responses: The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region... Agent:

20110052574 - Method of inhibition of leukemic stem cells: A method for inhibition of leukemic stem cells expressing IL-3Rα; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3Rα (CD123). The invention includes the treatment... Agent:

20110052570 - Method to prognose response to anti-egfr therapeutics: The present invention provides methods to determine the likelihood of effectiveness of an EGFR targeting treatment in a subject affected with a tumor based on the expression of EGFR of endothelial cells associated with the tumor. The present invention also provides methods of treating a subject affected with, or at... Agent:

20110052583 - Pyridinone compounds: e

20110052572 - Regulators of mmp-9 and uses therof: A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9. Molecules capable of specifically interacting with the OG domain, methods of identifying same, pharmaceutical compositions comprising same and uses... Agent:

20110052580 - Use of picoplatin and bevacizumab to treat colorectal cancer: The invention provides a method of treatment of metastatic colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with bevacizumab (Avastin®) and optionally, with 5-FU and leucovorin in a variety of treatment regimens. The invention also provides a use of picoplatin in conjunction with bevacizumab and, optionally,... Agent:

20110052581 - Use of picoplatin and cetuximab to treat colorectal cancer: The invention provides a method of treatment of metastatic colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with cetuximab, 5-FU, and leucovorin in a variety of treatment regimens. The invention also provides a use of picoplatin in conjunction with cetuximab, 5-FU, and leucovorin for treatment of... Agent:

20110052576 - Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an... Agent:

20110052585 - Compositions and methods for inhibiting interleukin pathways: Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23... Agent:

20110052586 - Antibodies to an epitope of agr2, assays and hybridomas: Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be... Agent:

20110052589 - Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.... Agent:

20110052592 - Compositions and methods for use for antibodies against sclerostin: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.... Agent:

20110052588 - Method of treating hepatocellular carcinoma: Materials and methods for treating hepatocellular carcinoma in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and... Agent:

20110052590 - Neutrokine-alpha antibodies and methods of use thereof: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders... Agent:

20110052587 - Peptide or protein comprising a c'-d loop of the cd28 receptor family: The invention relates to a protein or peptide comprising the C′-D loop of a member of the CD28 family, uses thereof and mAbs obtainable therefrom.... Agent:

20110052591 - Variants of thyroid stimulating hormone beta: Polynucleotide and polypeptide sequences that encode novel variants of mouse or human thyroid stimulating hormone-β proteins are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications to prevent, treat or reduce the severity of thyroid stimulating hormone-β-related disorders.... Agent:

20110052593 - Breast cancer associated antigen: The invention relates to nucleic acid and amino acid sequences encoding BUC11 (SEQ ID NO: 36), BUC6 (SEQ ID NO: 31), BUC9 (SEQ ID NO: 32), and BUC10 (SEQ ID NO: 35), and to the use of such sequences in the identification and treatment of cancers.... Agent:

20110052594 - Agents that dissolve arterial thrombi: Agents that induce platelet fragmentation include an IgG antibody that reacts with platelet epitope GPIIIA49-66 on platelet membrane, recombinant AMANTS-18, phorbol 12-myristate 13-acetate (PMA) and A23817.... Agent:

20110052596 - Antibodies to il-17a: Engineered antibodies to human IL-17A are provided, as well as uses thereof.... Agent:

20110052595 - Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.... Agent:

20110052597 - Anti-il-13r alpha1 antibodies and their uses thereof: Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present... Agent:

20110052599 - Facilitation of oocyte, zygote and pre-implantation embryo maturation: Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented... Agent:

20110052600 - Il-17ra-il-17rb antagonists and uses thereof: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.... Agent:

20110052598 - Method for screening of therapeutic agent for allergic airway inflammation and/or airway hypersensitivity using il-17rb-positive nkt cell: The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of... Agent:

20110052601 - Compositions comprising anti-icam-1 antibodies: There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. method of preventing RSV infection by administering an effective amount... Agent:

20110052603 - method of treatment and agents useful for same: The present invention relates generally to a method of modulating tumor necrosis factor-mediated apoptosis and to agents useful for same. More particularly, the present invention contemplates a method of modulating tumor necrosis factor-mediated hepatocyte apoptosis by modulating an intracellular Bim and/or Bid-dependent signalling mechanism. The method of the present invention... Agent:

20110052605 - Assay for soluble cd200: The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels.... Agent:

20110052602 - Diagnosis and treatment of age related macular degeneration: Methods, compositions and kits for diagnosis and treatment of age related macular degeneration.... Agent:

20110052604 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.... Agent:

20110052606 - Humanized anti-human nkg2a monoclonal antibody: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.... Agent:

20110052607 - Methods of diagnosing myelodysplastic syndrome (mds) or leukemia using nucleic acids or fragments encoding flt3 kinase: To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the... Agent:

20110052608 - Novel antibodies against prion protein and uses thereof: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.... Agent:

20110052610 - Antibody composition exhibiting cellular cytotoxicty due to glycosylation: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for... Agent:

20110052609 - Magnetic transducers: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.... Agent:

20110052611 - Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form... Agent:

20110052613 - Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase: Provided is a method of increasing the stability of wild-type β-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of β-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a... Agent:

20110052612 - Spiropiperidine compound and medicinal use thereof: This antagonist is useful as a preventive, therapeutic and/or progression-suppressing agent for a CXCR3-mediated disease such as an immune or an allergic disease [e.g., an atopic disease, an autoimmune disease (e.g., multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, glomerulonephritis, Sjogren's syndrome and the like), systemic inflammatory response... Agent:

20110052616 - Biological materials and uses thereof: The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of... Agent:

20110052614 - Stat3 epitope peptides: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 19, 20, 21, 22, 26, 27, 29, 30, 59, 61, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 75, 77,... Agent:

20110052615 - Tumour-specific animal proteins: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.... Agent:

20110052617 - Aav scleroprotein, production and use thereof: The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.... Agent:

20110052618 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... Agent:

20110052619 - Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus: The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus,... Agent:

20110052620 - Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus: GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH2—W—X-L-Y—Z—CO2H wherein: X is a Spb 1 sequence; L is an optional linker; Y is a GBS-80 sequence; W is an... Agent:

20110052621 - Pcsk9 vaccine: The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in... Agent:

20110052622 - Reishi-mediated enhancement of human tissue progenitor cell adhesion and differentiation: The present disclosure provides medicinally active extracts and fractions, and methods for using the same to increase eukaryotic cell adhesion, to increase differentiation of eukaryotic cells to produce increased numbers of immature dendritic cells, to enhance or accelerate condrogenesis of MSCs, to maintain undifferentiated CD34+ hematopoietic stem cells, and to... Agent:

20110052623 - Dried microbial cells or microorganism extract containing stabilized (ss)-s-adenosyl-l-methionine and method for production of the dried microorganism cell or microorganism extract: Dried microbial cells or microbial extract containing (SS)-SAM in which the progress in SAM chemical degradation or (SS)-SAM epimerization is significantly delayed can be obtained by drying microbial cells or microbial extract containing S-adenosyl-L-methionine (SAM), followed by maturing treatment. It is possible to stabilize SAM in a composition comprising dried... Agent:

20110052624 - Type 5 and type 8 capsular polysaccharides of overproducing s. aureus strains: The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing S. aureus strains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.... Agent:

20110052625 - Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide: Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce... Agent:

20110052626 - Leporipoxvirus-derived vaccine vectors: The invention relates to modified leporipoxyinises expressing a chimeric envelope protein resulting from the fusion of an envelope protein of mature intracellular virions or of an envelope protein of enveloped extracellular virions, with an exogenous protein. These modified leporipoxviruses can be used in particular for obtaining vaccines.... Agent:

20110052627 - Recombinant modified vaccinia virus measles vaccine: The invention concerns methods, compositions and kits for use in preparing a medicament and vaccine for measles virus comprising an Attenuated Modified Vaccinia Virus Ankara (MVA) strain encoding hemagglutinin protein, fusion protein, and nucleoprotein of measles virus (MVA-Measles). The recombinant virus induced superior cellular and humoral responses to the measles... Agent:

20110052629 - Methods of reducing concomitant infections in pigs with a pcv2 antigen: The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers... Agent:

20110052628 - Recombinant double-stranded rna phage, and use of the same: A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues.... Agent:

20110052630 - Compositions and methods using herpes simplex virus: Provided herein are methods and compositions for use in treating HSV-related conditions and diseases.... Agent:

20110052632 - Hiv polynucleotides and polypeptides derived from botswana mj4: The present disclosure relates to novel polynucleotides that encode HIV Env polypeptides. In particular, the disclosure relates to sequences derived from HIV strain Botswana MJ4 encoding Env polypeptides. Compositions comprising these polynucleotides and methods of using these polynucleotides are also disclosed.... Agent:

20110052631 - Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells: Provided is a method of activating an immune cell of a subject with Human Immunodeficiency Virus (HIV), comprising contacting the immune cell with a phorbol ester and a calcium ionophore. Also provided is a composition comprising immune cells of a subject diagnosed with HIV, wherein the immune cells are activated... Agent:

20110052633 - Multi-phase emulsions based on amphiphilic block copolymers: An composition comprises (a) a continuous aqueous phase; (b) an oily phase; and (c) an amphiphilic emulsifying system comprising a block copolymer having the formula (A)p-(B)q-(C)r, in which (B)q is a hydrophilic block and (C)r is a hydrophobic block; wherein p, q and r are integers with the proviso that:... Agent:

20110052634 - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof: The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention... Agent:

20110052635 - Live attenuated salmonella vaccine: The present invention is related to double and triple attenuated mutant strains of a bacterium infecting veterinary species such as Salmonella enterica and/or (a pathogenic) Escherichia coli. The mutants of the invention contain at least one first genetic modification and at least one second genetic modification, said first modification in... Agent:

20110052636 - Method for treating premature ejaculation with a botulinum neurotoxin: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.... Agent:

20110052637 - Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as vaccines: The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as vaccines.... Agent:

20110052638 - Allergens from aspergillus versicolor, and method of detecting a mold allergy caused by interior rooms: The invention relates to seven allergens of Aspergillus versicolor which are suitable for specific diagnostics of this mold which predominantly pollutes the interior. The invention is also directed to an immunological method of detecting a sensitization to A. versicolor, especially an allergy, wherein one or more of the above-mentioned seven... Agent:

20110052639 - Allergen mutants: Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall α-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.... Agent:

20110052640 - Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies: The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from D. pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites. Specifically, the invention describes hybrid proteins composed of fragments of allergens Derp p 1 y Derp p 2 with... Agent:

20110052641 - Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms: Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these... Agent:

20110052642 - Peripheral zone tumor cells, methods for their preparation and use: The present invention relates to a tumor cell of the peripheral zone of a tumor and methods of providing such a tumor cell. Further provided is a method for identifying a molecular marker diagnostic for an infiltrative cancer, an antibody, which specifically binds to such molecular marker, a method for... Agent:

20110052644 - Composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response: The present invention relates to a composition for improving intestinal flora and enhancing immune response containing Cinnamomum cassia bark extract as an effective ingredient, more precisely, a composition containing Cinnamomum cassia bark extract is an effective ingredient that has the effects of increasing the growth of such intestinal beneficial bacteria... Agent:

20110052643 - Compounds for inflammation and immune-related uses: The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent:

20110052647 - Antidepressant oral pharmaceutical compositions: Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its... Agent:

20110052645 - Manufacture of multiple minicapsules: An extrusion process comprises extruding a material that is flowable when heated and passing the extrudate thus formed through a nozzle 10 to shape the extrudate into a plurality of substantially uniformly shaped elements such as minispheres or minicapsules.... Agent:

20110052648 - Oral modified-release formulations containing thiazepines: An oral modified-release formulation using Quetiapine or pharmaceutically acceptable salts thereof as an active ingredient, while avoiding the use of a gelling material. As used herein, the term “modified release” includes but is not limited to one or more of controlled release, sustained release, prolonged release and extended release.... Agent:

20110052646 - Polymer adhesive film for directed cellular growth: The described embodiments relate to a polymer adhesive film having a micro-pattern arranged on a first surface of the polymer adhesive film for application to wounded tissue to promote directional cell growth. The micro-pattern is sized to allow cells of the wounded tissue to grow directionally within the micro-pattern to... Agent:

20110052649 - Fine powder of polyamide from renewable materials and method for making such a powder: The present invention relates to a powder of polyamide PA (homopolyamide or copolyamide) derived at least partially from renewable materials, in which the particles have a nonspherical shape and a volume median diameter of less than or equal to 20 μm. The present invention also relates to a process for... Agent:

20110052650 - Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest: The invention relates to solids made of a porous crystalline metal-organic framework (MOF) loaded with at least one gas of biological interest, and to a method for preparing the same. The MOF solids of the present invention are capable of adsorbing and releasing in a controlled manner gases having a... Agent:

20110052651 - Antimicrobial compositions and products: The present disclosure provides antimicrobial compositions for use in textiles, as well as methods of preparing these compositions and treating textiles with these compositions.... Agent:

20110052652 - Solid pharmaceutical composition comprising agglomerated nanoparticles and a process for producing the same: The present invention relates to pharmaceutical compositions comprising at least one active ingredient delivered by a nanoparticle. More specifically, the invention relates to solid pharmaceutical compositions comprising nanoparticles, wherein the nanoparticles are in the form of agglomerates with elevated equivalent aerodynamic diameters. The invention further relates to a process for... Agent:

20110052653 - Multi-purpose item rest: A multipurpose item rest having a bottom sheet with a non-absorbent surface with an absorbent pad fixedly attached thereto, an outwardly extending tab integral to the bottom sheet having an adhesive area such that the rest may be formed into a restraining device by applying the adhesive are to the... Agent:

20110052655 - Methods and vesicles for controlling protozoa: A method for controlling protozoa trophozoites and cysts wherein one or more biocides or non-biocidal agents are encapsulated within a micro-capsule or nano-capsule and then introduced into an aqueous system. The micro-capsule or nano-capsule has an exterior composition adapted for digestion by the protozoa. A vesicle for controlling protozoa trophozoites... Agent:

20110052654 - Microencapsulated insecticide formulations: Various microencapsulated insecticide formulations for the control of pests such as aphids and beet army worm. These formulations exhibit excellent knockdown activity towards both chewing and non-chewing pests as LD50 values for toxicity in female rats in the range of about 2,500 mgKg−1. Some of these formulations include a wall... Agent:

20110052656 - Method for controlling microbial biofilm in aqueous systems: A process has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of... Agent:

20110052657 - Implants for administering substances and methods of producing implants: A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant may have a large number of holes... Agent:

20110052658 - Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration: The described invention provides compositions comprising at least one peptide of formula I for enhancing neurite outgrowth, neuroprotection, and nerve regeneration, and methods of use thereof.... Agent:

20110052660 - Ceramic scaffolds for bone repair: Ceramic articles as functional biodegradable scaffolds with graded porosity are made by a process that includes a hardening step in which the liquid of a liquid-containing ceramic composition is extracted from the ceramic composition by exposing the ceramic composition to a solvent in which the liquid in the composition is... Agent:

20110052659 - Implants for administering substances and methods of producing implants: A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant may have a large number of holes... Agent:

20110052661 - Pet dental hygiene product: An edible product for oral hygiene of a pet, the product being chewable by the pet to remove plaque, tartar and stain from the teeth of the pet and to reduce breath odor of the pet. The dental hygiene product includes a body formed of a first set of constituent... Agent:

20110052662 - Antibacterial material and antibacterial film and antibacterial member using the same:

20110052664 - Antimicrobial medical dressings and protecting wounds and catheter sites: An antimicrobial medical dressing provides a combination of antimicrobial agents in various concentrations that protect against microorganisms, absorb exudates, and promote healing. The antimicrobial agents may include compositions of ethanol, hydrogen peroxide, and/or ethylenediaminetetraacetic acid.... Agent:

20110052665 - Haemostatic material: The present invention relates to a haemostatic material comprising a carrier layer and a material for wound contact comprising at least one haemostat in particulate, granular, powder, flake or short fibrous form. Such a haemostatic material is useful, for example, in reducing or stopping bleeding of a physiological target site... Agent:

20110052663 - Hemostatic sponge with enzyme and method of manufacture: In one embodiment, a method of making a wound dressing comprises dissolving at least one hemostatic agent in at least one solvent to form a solution. The method continues by freeze drying the solution to form a sponge. The method further comprises including an enzyme in the sponge that enables... Agent:

20110052674 - Angiotensin ii receptor blocker derivatives: New angiotensin II receptor blocker nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: and their use for treating cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndromes.... Agent:

20110052676 - Composition for delaying cellular senescence: Disclosed herein is a composition for delaying cellular senescence comprising from about 0.01 wt % to about 5 wt % of Hexapeptide-11(Phe-Val-Ala-Pro-Phe-Pro), based on the total weight of the composition, and a dermatologically-acceptable carrier for the peptide selected from the group consisting of water, oil, alcohol, silicone, and combinations thereof.... Agent:

20110052667 - Compositions and methods for inhibiting angiogenesis and tumorigenesis: The present invention relates to the regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, such as small organic molecules, antibodies, peptides and nucleic acids (e.g., antisense molecules, RNAi molecules and ribozymes), that modulate angiogenesis and tumorigenesis via modulation of IGF-II and, in... Agent:

20110052666 - Compositions, methods, and systems for sirna delivery: The instant invention provides silencer expression cassettes for delivery of RNAi therapy. The silencer cassettes of the instant invention encode an RNAi agent and lack means for replication within a host cell, inverted terminal repeats and further lacking one or more selectable markers. Optionally, the silencer cassettes lack CpG dinucleotides... Agent:

20110052668 - Identification and characterization of a specific cck-c receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer: Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.... Agent:

20110052670 - Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell: The present invention provides a molecular marker for the identification of pluripotent pre-mesenchymal, pre-hematopoietic stem cells. The invention further provides primitive progenitor cells identified by the molecular marker. Such cells have the potential to differentiate into both mesenchymal and hematopoietic phenotypes, as determined by a proliferative response to inductive growth... Agent:

20110052678 - Method for treating age related macular degeneration: A method for treating age related macular degeneration uses insulin preparation applied topically in a therapeutically effective amount to an affected conjunctival sac of the eye. The topically effective dose is delivered to the fovea centralis and macula lutea. In other embodiments, additional therapeutic, pharmaceutical, biochemical, nutriceutical, biological (monoclonal antibodies... Agent:

20110052669 - Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing,... Agent:

20110052677 - Modulation of srpx2-mediated angiogenesis: The present invention relates to nucleic acids and antibodies against SRPX2 and SRPX2 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the SRPX2 antagonists or agonists, respectively.... Agent:

20110052671 - Near infra-red pulsed laser triggered drug release from hollow nanoshell disrupted vesicles and vesosomes: The disclosure provides drug delivery methods and compositions. More particularly, the application provides liposomal delivery compositions comprising a nanostructure.... Agent:

20110052675 - Orally disintegrting forms for sustained release and controlled release: Orally disintegrating forms with sustained release capability and a method of making thereof are provided.... Agent:

20110052673 - Therapeutic compositions: Therapeutic compositions containing therapeutic agents and nitrogen-containing lipids are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles, microparticles, and complexes containing lipid/therapeutic agent complexes are also described.... Agent:

20110052672 - Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy: Methods are provided for the treatment of diseases and disorders using systematically-introduced nanoparticles to create a focused localized hyperthermia in a target area to enhance the effect of additional treatment therapies such as ionizing radiation. Advantages include an enhancement of the therapeutic effect of other therapies by increasing perfusion or... Agent:

20110052680 - Encapsulation of oxidatively unstable compounds: An encapsulated material containing an oxidation-sensitive core is covered by at least a dried phospholipid layer, and contains at least one phytosterol in the core, the phospholipid layer or in a further layer or layers. By using microencapsulation, oxidatively unstable materials may be provided with a synthetic protective barrier and... Agent:

20110052681 - Pharmaceutical compositions of entacapone co-micronized with sugar alcohols: The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.... Agent:

20110052679 - Solid naproxen concentrates and related dosage forms: The invention provides a composition consisting essentially of a solid naproxen concentrate, wherein the solid naproxen concentrate comprises (a) a solid naproxen free acid and (b) a solid naproxen alkali salt, and wherein at least 90% of the weight of the solid naproxen concentrate is naproxen free acid and naproxen... Agent:

20110052682 - Methods for enhancing the release and absorption of water insoluble active agents: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The... Agent:

20110052683 - Pharmaceutical preparation for treating cardiovascular disease: The present invention provides a pharmaceutical preparation comprising a prior-release compartment containing a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor as a pharmacologically active ingredient, and a delayed-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. The preparation of the present invention provides synergistic effects through combined administration of... Agent:

20110052684 - Pharmaceutical composition: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable... Agent:

20110052685 - Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen: Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.... Agent:

20110052686 - Modified release lamotrigine tablets: The present invention relates to uncoated modified-release tablets of lamotrigine and the process for preparation thereof, wherein the tablets comprise a portion of lamotrigine in an admixture with a pH-dependent polymer.... Agent:

20110052687 - Extended release pharmaceutical composition of paliperidone: The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and a water soluble and/or gellable polymer and optionally an enteric polymer.... Agent:

20110052688 - Solid dispersion composition: A solid dispersion extended release tablet composition is provided. The composition comprises fluvastatin sodium and a polymer, wherein molecules of the fluvastatin sodium are separate from one another and dispersed in the polymer, and wherein the composition displays two distinct peaks at about 3.5 and 20.4.degrees 2θ of X-ray diffraction.... Agent:

20110052689 - Sustained release of guaifenesin: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of... Agent:

20110052690 - Process for manufacture of a medicament with granulation and pan coating: A process for the manufacture of a coated tablet comprising a serotonin-norepinephrine reuptake inhibitor (SNRI), such as venlafaxine. According to one embodiment of the present invention, there is provided a process for manufacturing a coated tablet containing a serotonin-norepinephrine reuptake inhibitor, the process comprising preparing a granulate of the serotonin-norepinephrine... Agent:

20110052696 - Dendrimers with interior and exterior functionalities comprising of azide or alkyne groups for post-functionalization by the huisgen click cycloaddition: A dendritic structure includes a core and repeating units, wherein the repeating units comprise units of the type ABxCy, wherein x is 2, 3, or 4, wherein y is 1, 2, or 3, wherein C is selected from the group consisting of azides and alkynes, and wherein every repeating unit... Agent:

20110052695 - Drug delivery platforms comprising silk fibroin hydrogels and uses thereof: The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.... Agent:

20110052693 - Method for producing artificial skin: An object of the invention is to provide artificial skin that does not contain any animal-derived material or pathogen and has excellent biocompatibility. The invention provides, as a solution means, a method for producing artificial skin comprising the steps of: (A) forming a dermal layer by solidifying a mixture of... Agent:

20110052692 - Novel hydrogels and uses thereof: The present invention provides novel hydrogels and methods of making and using such hydrogels. The present invention provides hydrogels that may be formed by the self-assembly of peptides in solution. Such self-assembly may be brought about by a change in one or more characteristics of the solution. Characteristics of the... Agent:

20110052691 - Sustained release systems and preparation method thereof: The present invention relates to a hydrophilic drug and β-tricalcium phosphate (β-TCP) coating on a surface area of biopolymer matrix to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising providing a surface are of biopolymer matrix coated with a... Agent:

20110052694 - Use of cannabidiol prodrugs in topical and transdermal administration with microneedles: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug... Agent:

20110052697 - Aptamer-directed drug delivery: The present invention provides systems, methods, and compositions for targeted delivery of a therapeutic agent organs, tissues, cells, extracellular matrix components, and intracellular compartments. The present invention provides a complex comprising a therapeutic or diagnostic agent and a nucleic acid targeting moiety, wherein the agent non-covalently associates with base pairs... Agent:

20110052699 - Drug delivery system with stabilising effect: e

20110052700 - Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride: Gastric retentive oral dosage forms which provide both immediate and extended release of levosulpiride are described which may allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.... Agent:

20110052698 - Novel material with bacteriostatic properties: The invention relates to a method for making a composite material including a porous polymer matrix containing HEMA monomers and in which silver nanoparticles are dispersed, and to the use thereof as an anti-microbial material.... Agent:

20110052703 - Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents: Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the... Agent:

20110052705 - Cartilage composition and process for producing the cartilage composition: Disclosed is a method for regenerating articular cartilage in an animal comprising administering a therapeutically effective amount of a non-demineralized particulate articular cartilage having a distribution of particle sizes within the range of from about 60 microns to about 500 microns.... Agent:

20110052702 - Method and apparatus for producing organic nanotubes: An apparatus for producing organic nanotubes according to the present invention includes: a tank that contains an organic nanotube material dispersion solution consisting of an organic nanotube material and an organic solvent; a pump that pressurizes the organic nanotube material dispersion solution from the tank so that the organic nanotube... Agent:

20110052701 - Particulates of a crth2 antagonist: Provided herein are particulates of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid in amorphous or crystalline forms, processes for their preparation, pharmaceutical compositions comprising them, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.... Agent:

20110052704 - Tocotrienol compositions: Compositions containing tocotrienol, non-tocotrienol lipids and surface active agents; compositions containing particles having a statin and a tocotrienol wherein the particle size is less than 1000 nm; and microemulsions containing a statin and a tocotrienol are disclosed. Methods relating to the creation of such compositions and the use of such... Agent:

20110052707 - Combination of vitamin d and 25-hydroxyvitamin d 3: We disclose compositions comprising Vitamin D (cholecalciferol and/or ergocalciferol) and 25-OH D3 (calcifediol), and use of those compositions to affect at least concentration, bioavailability, metabolism, or efficacy of vitamin D in a human. Forms and dosages of the composition, as well as processes for manufacturing a spray-dried formulation, are also... Agent:

20110052706 - Pancreatine pellets and method of producing same: In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.... Agent:

20110052708 - Methods and formulations for the delivery of pharmacologically active agents: In accordance with the present invention, novel formulations have been developed which are much more effective for the delivery of hydrophobic drugs to patients in need thereof than are prior art formulations. Invention formulations are capable of delivering more drug in shorter periods of time, with reduced side effects caused... Agent:

20110052709 - Novel nanoparticles for delivery of active agents: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.... Agent:

20110052710 - Novel nanoparticles for delivery of active agents: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.... Agent:

20110052711 - Controlled release multidrug formulations for spinal cord injury: A controlled release multidrug formulation for improving locomotor recovery after spinal cord injury comprising: (a) a first composition comprising a first bioactive agent, encapsulated within a first polymeric particle; (b) a second composition comprising a second bioactive agent, encapsulated within a second polymeric particle, wherein the second polymeric particle is... Agent:

20110052713 - Repairing damaged nervous system tissue with nanoparticles: The present application relates to reduction of acrolein-mediated cell death following neural insult. According to at least one embodiment, chitosan is utilized as a membrane fusogen to restore cell function. According to at least one other embodiment, chitosan or silica is used to create a non-toxic polymer surfaced microcolloid (PSM).... Agent:

20110052712 - Sprayable polymers as adhesion barriers: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The... Agent:

20110052714 - Organic polymer-inorganic fine particle antimicrobial composites and uses thereof: An embodiment relates to a composition comprising a noble-metal containing nanoparticle and a polymer located on a surface of the nanoparticle, wherein the polymer is a polycondensation product of a halogenated monomer. Other embodiments relate to the method of making a composition and providing antimicrobial treatment using the composition.... Agent:

20110052716 - Adjuvant comprising aluminum, oligonucleotide and polycation: An immunological adjuvant comprises an aluminium salt, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be included in a composition with an immunogen e.g. to elicit an immune response that protects against a... Agent:

20110052715 - Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well... Agent:

20110052717 - Slow release pharmaceutical composition made of microparticles: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form... Agent:

20110052718 - Synergistic phytoceutical compositions: Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants... Agent:

20110052719 - Dermatological composition that can be used in particular for the care and prevention of eschars: The invention relates to a composition formulated for a topical application to the skin containing, as essential constituents, peroxide lipids that have a degree of peroxidation between 30 and 500 milliequivalents per kg of peroxide lipids and cod liver oil. This composition can be used as a medical device, in... Agent:

20110052720 - Compositions for the control of plant pathogens and for use as plant fertilizer: The present invention relates to a composition comprising a metal compound, a lignosulfonate and phosphorous acid and/or a salt and/or a hydrate and/or an ester thereof and its use as fungicide, bactericide or fertilizer and its use in preventing the formation of a metal phosphite precipitate in an aqueous composition.... Agent:

20110052721 - Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal... Agent:

20110052722 - Toleration iron supplement compositions: The invention relates to compositions and methods for the treatment or prophylaxis of iron deficiency, and in particular of iron deficiency anemia, by administering a composition containing an effective amount of a pharmaceutically acceptable ferrous iron salt; and an effective amount of polysaccharide iron complex.... Agent:

20110052723 - Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy: The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.... Agent:

20110052724 - Calcium hypochlorite compositions: Described are compositions containing a mixture of (a) particulate calcium hypochlorite and (b) an amount of aluminum hydroxide that is sufficient to increase the UN-burn time of the composition by a factor of at least 2.5 compared to that of the calcium hypochlorite, the composition having an available chlorine content... Agent:

20110052726 - Solid-layered bleach compositions and methods of use: The present invention provides a solid-layered composition having at least two parts. The first part comprises a) calcium hypochlorite, magnesium hypochlorite and mixtures thereof, b) a builder, c) a water-soluble polymer, d) an acid, and e) wherein the first part does not contain sodium hypochlorite, lithium hypochlorite, potassium hypochlorite and... Agent:

20110052725 - Therapeutic agent for infectious skin and mucosal disease: A therapeutic agent for infectious skin and mucosal diseases to be applied to an infected area for ameliorating a symptom of the infected area caused by infection with a pathogenic microorganism includes: a chlorine dioxide solution including a dissolved chlorine dioxide gas.... Agent:

20110052727 - Anti influenza nutritional supplements: The invention presents nutritional supplements with anti influenza activities. In a preferred embodiment, the invention features administration to a subject an effective dose of a nutritional supplement that includes a combination of all or some of the following ingredients licorice, quercetin, green tea, cinnamon, propolis, and selenium.... Agent:

20110052728 - Botanical extract from the aqueous stream of the palm oil milling process for the prevention and inhibition of oxidative stress and haemolysis in human red blood cells: The invention provides a composition for the prevention and inhibition of oxidative stress and haemolysis in human red blood cell wherein said composition compounds obtained from the aqueous stream of palm oil milling (palm oil vegetation liquor), in particular from vegetative liquor from the milling of palm oil fruit.... Agent:

20110052729 - Pharmaceutical or nutraceutical composition: The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects... Agent:

20110052730 - Leaves extract of panax sp., a process of making the same and uses thereof: The present invention relates to a composition for improvement of exercise performance, fatigue recovery or prevention of oxidation response comprising Panax species plant leaves extract or processed product of the leaves extract, or mixture of the both as an active ingredient. The present composition comprising Panax species plant leaves extract... Agent:

20110052731 - Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same: The present invention relates to an extract of a processed herbal medicinal plant and a composition for skin external application which contains the extract. More specifically, the composition for skin external application contains an extract of processed herbal medicinal plant, prepared through a method comprising the steps of: (a) processing... Agent:

20110052733 - Herbal compositions for the treatment of mucosal lesions: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the... Agent:

20110052732 - Mineral absorption accelerator and iron deficiency anemia improver of food composition: A mineral absorption accelerator, and an anemia improving agent, food and drink or food and drink material containing the mineral absorption accelerator are provided, the mineral absorption accelerator including: an α-glucosidase inhibitory component.... Agent:

20110052734 - Transparent oil gelling system: The invention relates to a gellant system for a polar oil comprising gellant effective amounts of silica, a sugar fatty acid ester and a long chain polymer. The gellant system of the invention is useful in gelling polar oils to produce transparent or translucent gels useful in topical compositions.... Agent:

20110052735 - Shampoo with fruit juice and/or vegetable juice: Shampoos providing hair treated therewith improved strength, handle and tensile strength, as well as combability in the dry and wet states and, at the same time, are particularly mild and ecologically compatible, and contain, in a cosmetically acceptable carrier, 0.1 to 35% by weight of at least one surfactant and... Agent:

20110052736 - Methods and materials for reducing or eliminating risk factors associated with syndrome x: A composition containing cinnamon extract reduces and/or eliminates one or more risk factors associated with Syndrome X. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing... Agent:

20110052737 - Topical skin formulations comprising botanical extracts: Disclosed are compositions and corresponding methods of their use that include Nymphaea gigantea, Syzygium moorei, Cupaniopsis anacardioides, Archidendron hendersonii, Tristaniopsis laurina, Brachychiton acerifolius, Stenocarpus sinuatus, Alphitonia excelsa, Eucalyptus coolabah, Plumeria alba, Cocos nucifera, or Tamarindus indica extract.... Agent:

20110052738 - Topical pain formulation: A topical pain formulation, comprising one or more analgesic compounds and a plurality of skin penetrants.... Agent:

20110052739 - Active ingredient that stimulates the proliferation and/or activity of fibroblasts: The invention relates to a novel active ingredient that stimulates the proliferation and/or the activity of fibroblasts and also to its applications in the cosmetic or pharmaceutical, in particular dermatological, field. In particular, the active ingredient according to the invention comprises a combination of at least one Hibiscus Abelmoschus extract... Agent:

20110052740 - Skin circulation-improving agent and skin temperature-elevating agent: Skin blood circulation is improved, skin temperature is increased, or shoulder stiffness or sensitivity to cold is prevented or improved by using, as an active ingredient, at least one of the members selected from the group consisting of an Arabian jasmine (matsurika, jasmin sambac) extract, a damask rose (Rosa damascena)... Agent:

20110052741 - Composition and method for skin repair: A composition and a method of using the composition is described that is effective to protect or repair oxidative damage to DNA in mammalian skin by up regulating each of SIRT1, Gadd45b, and SOD2. The composition includes at least two of a candle bush extract, noni leaf extract, and melon... Agent: